Page last updated: 2024-08-21

pyrazines and Diabetes Mellitus, Type 2

pyrazines has been researched along with Diabetes Mellitus, Type 2 in 586 studies

Research

Studies (586)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	34 (5.80)	18.2507
2000's	147 (25.09)	29.6817
2010's	401 (68.43)	24.3611
2020's	4 (0.68)	2.80

Authors

Authors	Studies
Chen, H; Chen, X; Fan, M; Sun, T; Sun, W; Tong, H; Wu, X; Yin, Z; Zhang, C; Zhang, H; Zheng, X; Zhu, Y	1
Allen, M; Chorlton, J; Hollowood, Z; Lockhart, D; Martin, J; McCafferty, K	1
Akhtar, A; Chopra, K; Dhaliwal, J; Dhaliwal, N; Kuhad, A	1
Birla, H; Kosuru, R; Prakash, S; Rai, U; Singh, S; Singh, SP; Tiwari, V	1
Kosuru, R; Prakash, S; Rai, U; Singh, S; Tiwari, V	1
Cui, F; Hu, M; Huang, L; Zhao, Y	1
Hansen, D; Minten, L; Smeets, K; van Dijk, JW; van Loon, LJC; Verboven, K; Verdijk, LB; Zorenc, A	1
Miyazaki, S; Mori, Y; Taniguchi, Y; Utsunomiya, K; Yokoyama, J	1
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F	2
Gondo, S; Hiwatashi, A; Ikeda, H; Inoue, T; Iwamoto, T; Kodama, K; Kuroki, S; Node, K; Oyama, J; Sakamoto, Y; Shimomura, M; Taguchi, I; Uchida, Y	1
Banks, P; Ding, ZM; Frazier, K; Freiman, J; Ogbaa, I; Powell, D; Ruff, D; Sands, A; Smith, M; Turnage, A; Zambrowicz, B	1
Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E	1
Chang, HY; Clark, JM; Richards, TM; Segal, JB; Singh, S; Weiner, JP	1
Cohen, D	1
Blétry, O; Bouilloud, F; Crickx, E; Kahn, JE; Le Beller, C; Marroun, I; Schoindre, Y; Veyrie, C	1
Johnsson, E; Leonsson-Zachrisson, M; Wessman, C; Wilding, JP	1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M	1
Grunberger, G	1
Flessner, MF; St Peter, WL; Weinhandl, ED	2
Drake, AJ; Iyer, SN; Mendez, CE; Tanenberg, RJ; West, RL	1
Hayashi, N; Johnsson, E; Kiyosue, A; Komori, H; Leonsson-Zachrisson, M	1
Atkinson, M; Butler, AE; Butler, PC; Campbell-Thompson, M; Dawson, DW; Gurlo, T	1
Ayaori, M; Iizuka, M; Ikewaki, K; Iwakami, N; Komatsu, T; Murakami, T; Nakaya, K; Ogura, M; Sasaki, M; Sato, H; Takase, B; Takiguchi, S; Uto-Kondo, H; Yakushiji, E; Yogo, M	1
Defronzo, RA; Dubé, JJ; Espinoza, S; Liang, H; Mohan, S; Musi, N; Shanmugasundaram, K; Sriwijitkamol, A; Tantiwong, P	1
Gavish, D; Gevrielov-Yusim, N; Goldenberg, I; Gottlieb, S; Leibovitz, E; Matetzky, S	1
Hunt, B; Langer, J; Valentine, WJ	1
Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J	1
Alexander, CM; Brodovicz, KG; Engel, SS; Girman, CJ; Kou, TD; O'Neill, EA; Senderak, M	1
Ishibashi, S; Kotani, K; Nagashima, S; Okada, K; Osuga, J; Ozaki, K; Takahashi, M; Yagyu, H; Yamazaki, H	1
Bhargava, A; Del Prato, S; Dharmalingam, M; Garber, AJ; Philis-Tsimikas, A; Rasmussen, S; Satman, I; Skjøth, TV	1
Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C	1
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H	1
Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L	1
Asche, CV; Eurich, DT; McAlister, FA; Sandhu-Minhas, JK; Senthilselvan, A; Simpson, S	1
Ando, K; Morimoto, A; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K	1
Tang, Y; Wu, F; Xu, T; Zhan, M	1
Segal, J	1
Schütt, M; Steinhoff, J; Süfke, S	1
Charbonnel, B; Dejager, S; Schweizer, A	1
Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W	1
Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D	1
Bergeson, JG; Graham, J; Louder, A; Ward, M; Worley, K	1
Batra, M; Chaudhuri, A; Dandona, P; Kuhadiya, N; Makdissi, A	1
Bruce, SS; Connolly, ES; Heyer, EJ; Mergeche, JL	1
Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S	1
de Oliveira, JM	1
Eurich, DT	1
Scheen, AJ	9
Han, J; Malloy, J; Meloni, A	1
Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS	1
Ahrén, B; Alba, M; Goldstein, BJ; Guan, Y; Inzucchi, SE; Kaufman, KD; Mallick, M; O'Neill, EA; Williams-Herman, DE; Xu, L	1
Moniri, NH; Ryan, GJ; Smiley, DD	1
Cander, S; Cinkilic, N; Ersoy, C; Gul, CB; Oz Gul, O; Tuncel, E; Vatan, O; Yılmaz, D	1
Farrokhi, F; Gianchandani, R; Jacobs, S; Lathkar-Pradhan, S; Newton, C; Pasquel, F; Peng, L; Reyes, D; Smiley, D; Umpierrez, GE; Wesorick, DH	1
Huang, Q; Peng, Y; Wang, Y; Zhao, L	1
Chou, MZ; Fonseca, VA; Goldstein, BJ; Golm, GT; Henry, RR; Kaufman, KD; Langdon, RB; Staels, B; Steinberg, H; Teng, R	1
Araki, E; Furukawa, N; Goto, R; Ichimori, S; Iwashita, S; Kawashima, J; Kondo, T; Maeda, T; Matsumura, T; Matsuo, T; Matsuo, Y; Motoshima, H; Nishida, K; Sekigami, T; Shimoda, S	1
Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY	1
Harja, E; Lord, J; Skyler, JS	1
Dang, NH; Hatano, R; Morimoto, C; Ninomiya, H; Ohnuma, K; Saito, T; Suzuki, H	1
Derosa, G; Maffioli, P	2
Arjona Ferreira, JC; Goldstein, BJ; Golm, GT	1
Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A	1
Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C	1
Bain, SC; Eligar, VS	1
Cho, JH; Kim, ES; Kim, HS; Lee, SH; Shin, JA; Son, HY; Yoon, KH	1
Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C	1
Kawata, T; Matsubara, F; Nagai, Y; Nakamura, Y; Ohshige, T; Ohta, A; Sakai, K; Tanaka, Y; Tenjin, A; Terashima, Y; Tsukiyama, S	1
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F	2
Al-Shurbaji, A; Denison, H; Eriksson, JW; Himmelmann, A; Knutsson, M; Löfgren, L; Mårtensson, G; Nilsson, C; Tornqvist, H	1
Hardy, E; Jabbour, SA; Parikh, S; Sugg, J	1
Arndt, E; Deacon, CF; Holst, JJ; Nauck, MA; Vardarli, I	1
Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ	1
Li, H; Lu, J; Zang, J	1
Fujita, H; Hayashi, H; Kikuchi, N; Komatsu, K; Komatsu, T; Murayama, H; Narita, T; Ohshiro, H; Sato, S; Taniai, H; Yamada, Y	1
Huh, W; Jung, JA; Kaku, K; Kim, JH; Kim, JR; Ko, JW; Lee, SY	1
Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR	1
Aulinger, BA; Bedorf, A; de Heer, J; Göke, B; Holst, JJ; Kutscherauer, G; Schirra, J	1
Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH	1
De Maeyer, N; Delforge, M; Dierickx, D; Meersseman, W; Wauters, J	1
Scheen, AJ; Van Gaal, LF	3
Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J	1
Sakr, HF	1
Anz, D; Bourquin, C; Endres, S; Haubner, S; Kruger, S; Rapp, M	1
Abdul-Ghani, M; Clarke, GD; Daniele, G; DeFronzo, RA; Eldor, R; Merovci, A; Taranova, A; Tripathy, D; Xiong, J	1
Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S	1
Plosker, GL	1
Cunningham, C; Dey, M; Forest, T; Frederick, C; Holder, D; Prahalada, S; Smith, A; Yao, X	1
Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K	1
Deng, H; Ji, A; Yin, J	1
Schnell, O	1
Abe, J; Hara, H; Kinosada, Y; Nagasawa, H; Nakamura, M; Nishibata, Y; Suzuki, Y; Umetsu, R	1
Bond, SJ; Dutka, DP; Hoole, SP; Kydd, AC; McCormick, LM; Read, PA; Ring, LS	1
Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Round, EM	1
Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF	1
Amemiya, H; Honda, S; Hoshino, K; Iemitsu, K; Iizuka, T; Ishikawa, M; Iwasaki, T; Kanamori, A; Kaneshige, H; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Maeda, H; Matoba, K; Matsuba, I; Minagawa, F; Minami, N; Miyairi, Y; Miyakawa, M; Mokubo, A; Motomiya, T; Naka, Y; Nakajima, S; Obana, M; Saito, T; Sasai, N; Takai, M; Takeda, H; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y; Tsurui, N; Uehara, G; Umezawa, S; Waseda, M	1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Kumakura, A; Maeda, H; Shirabe, S; Yamamoto, R; Yamauchi, M	1
Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J	1
Hirata, T; Inukai, K; Ishida, H; Katayama, S; Morimoto, J	1
Tibaldi, JM	1
Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M	1
Ferrannini, E; Mari, A; Polidori, D	1
Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z	1
Dong, S; Jia, J; Mao, C; Qian, W; Tang, B; Wang, D; Yang, L; Ye, J; Yu, S; Yuan, G; Zhang, C; Zhou, L; Zhu, T	1
Broedl, UC; Delafont, B; Eilbracht, J; Kim, G; Roden, M; Weng, J; Woerle, HJ	1
Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK	1
Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T	1
Fukumoto, M; Hiura, Y; Hosoi, M; Ikuno, Y; Kawasaki, I; Okada, M; Tamai, A; Tanaka, N; Ueno, H; Yakusiji, Y; Yamagami, K; Yoshida, Y	1
Johnson, JL; Kim, MK; O'Neal, KS; Pack, CC	1
Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ	1
Bailey, CJ; Diamant, M; Fouqueray, P; Inzucchi, SE; Lebovitz, HE; Pirags, V; Schernthaner, G	1
Komatsu, M; Miya, K; Noma, Y; Shima, K	1
Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS	1
Athyros, VG; Elisaf, MS; Filippatos, TD	1
Bando, YK; Ishizu, T; Kodama, K; Murohara, T; Node, K; Oyama, J; Sato, Y	1
Atkinson, AM; Baker, DJ; Charles, AD; Coghlan, M; Jones, HB; Leighton, B; Wilkinson, GP	1
Garg, K; Kumar, S; Tripathi, CD	1
Agoramoorthy, G; Chakraborty, C; Hsu, MJ	1
Fernandes, R; Fontes-Ribeiro, C; Gonçalves, A; Marques, C; Mega, C; Reis, F; Rodrigues-Santos, P; Teixeira, F; Teixeira-Lemos, E	1
Nandith, A; Ramachandran, A; Shetty, AS; Snehalath, C	1
Ishida, H; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A	1
Funahashi, T; Hayashi, M; Hibuse, T; Hirata, A; Kashine, S; Kimura, T; Kishida, K; Maeda, N; Minami, T; Nakagawa, Y; Nishizawa, H; Oka, A; Shimomura, I; Takeshita, E	1
Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F	1
Hompesch, M; Krentz, AJ; Morrow, L; Norjavaara, E; Petersson, M	1
Guthrie, R; Slee, A; Traina, S	1
Chen, TY; Hsieh, CJ	1
Inden, Y; Ishii, H; Ishikawa, S; Koyasu, M; Murohara, T; Shimano, M; Takemoto, K; Uchikawa, T; Watarai, M	1
Barros, JI; Cunha, GH; d'Alva, CB; Fechine, FV; Fernandes, VO; Montenegro Júnior, RM; Moraes, ME; Moraes, MO; Souza, MH; Vale, OC	1
Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M	1
Persson, U; Steen Carlsson, K	1
Katoh, N; Nakai, N	1
Fuller, CS; Gallop, R; Gudipaty, L; Rickels, MR; Rosenfeld, NK; Schutta, MH	1
Eurich, DT; McAlister, FA; Minhas-Sandhu, JK; Senthilselvan, A; Weir, DL	1
Bhatt, DL; Cavender, MA	1
Doggrell, SA; Tuli, R	1
Jin, D; Sakonjo, H; Takai, S	1
Couture, P; Deacon, CF; Lamarche, B; Tremblay, AJ; Weisnagel, SJ	2
Baldi, S; Casolaro, A; Cobb, J; Ferrannini, E; Frascerra, S; Gall, W; Mari, A; Muscelli, E	1
Carr, MC; Handelsman, Y; Jones-Leone, A; Leiter, LA; Scott, R; Stewart, M; Yang, F	1
Charest, A; Couture, P; Droit, A; Kelly, I; Lamarche, B; Lépine, MC; Tremblay, AJ	1
Coen, PM; Goodpaster, BH	1
Fukuda, S; Hirata, K; Ito, H; Kihara, H; Miyoshi, T; Nakamura, K; Oe, H; Shimada, K; Takagi, T; Watanabe, K; Yoshikawa, J; Yunoki, K	1
Gou, Z; Ma, M; Wang, F; Wang, T; Zhai, SD	1
Ban, N; Kawana, H; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Yamaguchi, T	1
Al-Khalili, L; Cuesta, PG; de Castro Barbosa, T; Katayama, M; Massart, J; Nyström, AC; Oscarsson, J; Osler, ME; Ostling, J; Zierath, JR	1
Inoue, T; Kyou, C; Morishita, K; Ogawa, T; Taguchi, Y; Umayahara, R; Yonemoto, T	1
Asai, S; Kato, H; Kondo, A; Nagai, Y; Ohta, A; Sada, Y; Sasaoka, T; Tanaka, Y	1
Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S	1
Kourlaba, G; Maniadakis, N; Melidonis, A; Tzanetakos, C; Verras, C	1
Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP	1
Ametov, AS; Gusenbekova, DG	1
Ando, K; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K	1
Jabbour, S	1
Auwerx, J; Bierwagen, A; Bilet, L; Havekes, B; Hesselink, MK; Hwang, JH; Livingstone, R; Moullan, N; Nowotny, P; Paglialunga, S; Phielix, E; Pirinen, E; Roden, M; Ropelle, ER; Schrauwen, P; Schrauwen-Hinderling, VB; Sparks, LM; Szendroedi, J; van de Weijer, T; Williams, EG	1
Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G	1
Hong, D; Wu, B; Xiao, Y; Zhao, Q; Zheng, D	1
Hsieh, CJ; Shen, FC	1
Horikawa, Y; Mikada, A; Narita, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H	1
Chopra, BS; Choudhary, V; Garg, R; Garg, V; Khatri, N; Peddada, N; Sagar, A	1
Akay, A; Dragomir, A; Erlandsson, BE	1
Doggrell, S	1
Thompson, AM; Trujillo, JM	1
Kabbara, WK; Ramadan, WH	1
Cornell, S	1
Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U	1
Avram, S; Borcan, F; Buiu, C; Duda-Seiman, C; Duda-Seiman, D; Milac, AL; Pacureanu, L	1
Bailey, RA; Blonde, L; Meininger, G; Rupnow, MF; Vijapurkar, U	1
Baek, JH; Huh, WS; Jin, SM; Jung, JA; Kaku, K; Kim, JH; Kim, JR; Kim, MJ; Ko, JW; Lee, SY	1
Armstrong, PW; Bethel, MA; Buse, JB; Engel, SS; Garg, J; Green, JB; Holman, RR; Josse, R; Kaufman, KD; Koglin, J; Korn, S; Lachin, JM; McGuire, DK; Pencina, MJ; Peterson, ED; Standl, E; Stein, PP; Suryawanshi, S; Van de Werf, F	1
Chen, DY; Chen, TH; Cherng, WJ; Chou, CC; Hsieh, IC; Hung, KC; Lin, YS; Mao, CT; Su, FC; Tsai, ML; Wang, CC; Wang, SH; Wen, MS	1
Markun, S	1
Zechmann, S	1
Holman, RR; Peterson, ED	1
Ashcroft, DM; Rutter, MK; Wright, AK	1
Kumar, HK	1
Kay, GN	1
Abdul-Ghani, M; Daniele, G; DeFronzo, RA; Mari, A; Merovci, A; Solis-Herrera, C; Tripathy, D; Xiong, J	1
Dimmitt, SB; Doggrell, SA	1
Kohara, N; Satoh, J; Sekiguchi, K; Yamaguchi, Y	1
Anderwald, CH; Baumgartner-Parzer, S; Fürnsinn, C; Harreiter, J; Kosi-Trebotic, L; Krebs, M; Krssak, M; Luger, A; Smajis, S; Trattnig, S; Winhofer, Y; Wolf, P	1
Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M	1
Aydar, M; Kitai, T; Krittanawong, C; Sun, T	1
Bailey, CJ; Flatt, PR; Green, BD	3
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H	1
Arellano, S; Di Girolamo, G; Gagliardino, JJ; Santoro, S	1
Amatruda, JM; Arjona Ferreira, JC; Chan, JC; Davies, MJ; Gonzalez, E; Kaufman, KD; Scott, R; Sheng, D; Stein, PP; Williams-Herman, D	1
Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S	1
Ahrén, B	5
Craddock, BP; Foreman, KW; Hubbard, SR; Ji, QS; Li, W; Miller, WT; Mulvihill, MJ; Wu, J	1
Elisaf, MS; Florentin, M; Liberopoulos, EN; Mikhailidis, DP	1
Pei, Z	1
Bax, JJ; de Boer, HH; de Roos, A; Hammer, S; Lamb, HJ; Romijn, JA; Smit, JW; van der Meer, RW	1
Gadsby, R	1
Doupis, J; Veves, A	1
Herman, G; Krishna, R; Wagner, JA	1
DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P	1
Campbell, RK; Neumiller, JJ; Reynolds, JK	1
Davidson, JA; Gross, JL; Parente, EB	1
Faust, M; Matthes, J	1
Fonseca, VA; John-Kalarickal, J; Wani, JH	1
Taéron, C	1
Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E	1
Feinglos, M; Green, J	1
Bandeira-Echtler, E; Bergerhoff, K; Lerch, C; Richter, B	1
Amatruda, JM; Kaufman, KD; Langdon, RB; Mohan, V; Noble, L; Son, HY; Stein, PP; Xu, L; Yang, W	1
Gupta, R; Pal, M; Parsa, KV; Singh, SK; Tokala, RK; Walunj, SS	1
Siddiqui, NI	1
Boye, KS; Fabunmi, R; Lage, MJ; Misurski, DA	1
Bergman, AJ; Davies, MJ; Dilzer, SC; Herman, GA; Lasseter, KC; Luo, WL; Migoya, EM; Stevens, CH; Wagner, JA	1
Amatruda, JM; Davies, MJ; Goldstein, BJ; Johnson, J; Kaufman, KD; Luo, E; Teng, R; Williams-Herman, D	1
Gallen, IW; Lumb, AN	1
Amatruda, JM; Fukao, Y; Johnson-Levonas, AO; Nonaka, K; Okuyama, K; Tsubouchi, H	1
Argyrakopoulou, G; Doupis, J	1
Nicolucci, A; Rossi, MC	1
Kripke, C	1
East, HE; Riche, DM; Riche, KD	1
Mikhail, N	2
Bril, V; Buchanan, R; Hirose, T; Tomioka, S	1
Butler, AE; Butler, PC; Cox, HI; Dry, S; Galasso, R; Gurlo, T; Matveyenko, AV; Moshtaghian, A	1
Gallwitz, B	6
Arjona Ferreira, JC; Horie, Y; Kanazu, S; Narukawa, M; Nonaka, K; Takeuchi, M; Taniguchi, T	1
Keating, N	1
Alexander, CM; Chapell, R; Gould, AL	1
Giampietro, O; Matteucci, E	1
Alba, M; Goldstein, BJ; Guan, Y; Herman, G; Kaufman, KD; Larson, P; Sachs, JR; Sheng, D; Thornberry, N; Williams-Herman, D	1
Cross, LB; Gentry, C; Gross, B; McFarland, MS; Patel, UP; Tunney, J	1
Gallwitz, B; Thornberry, NA	1
Eiermann, GJ; Feng, Y; Howard, AD; Li, C; Li, Z; Mu, J; Petrov, A; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E	1
Curtiss, FR; Fairman, KA	1
Bode, BW	1
Matthaei, S	1
Bischoff, A	1
Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA	1
Freeman, JS	2
Henson, K; Hight, R; Welborn, D; Wyatt, S	1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA	1
Alexander, CM; Siler, SQ; Topp, BG; Waters, SB	1
Hoerger, T; Pogach, L; Rajan, M; Sinha, A	1
Aschner, P; Goldstein, BJ; Guo, H; Katzeff, HL; Kaufman, KD; Sunga, S; Williams-Herman, D	1
Amatruda, JM; Andryuk, PJ; Cefalu, WT; Chen, Y; Engel, SS; Katz, L; Kaufman, KD; Ling, Y; Luo, E; Musser, B; Rosenstock, J; Vilsbøll, T; Yki-Järvinen, H	1
Cross, LB; Foard, J; Gross, BN; Wood, Y	1
Bilkovski, R; Faust, M; Freude, S; Krone, W; Laudes, M; Oberhauser, F; Schilbach, K; Schulte, DM; Schulz, O	1
Dhillon, S	1
Peters, A	1
Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S	1
Amatruda, J; Arjona Ferreira, JC; Iwamoto, Y; Nonaka, K; Okamoto, T; Okuyama, K; Taniguchi, T	1
Meier, JJ; Menge, BA; Schmidt, WE	1
Agostini, C; Albiero, M; Avogaro, A; Boscaro, E; de Kreutzenberg, S; Fadini, GP; Frison, V; Menegazzo, L; Tiengo, A	1
Bilan, VP; Jackson, EK; Tofovic, DS	1
Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T	1
Cefalu, WT	1
Clay, RJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Machotka, SV; Williams-Herman, DE	1
Amatruda, JM; Goldstein, BJ; Golm, G; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D	1
Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Montanya, E; Nauck, M; Pratley, RE; Søndergaard, RE; Thomsen, AB	1
Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S	1
Berria, R; Davis, KL; Horton, ES; Silberman, C	1
Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q	2
Guerci, B; Halter, C	1
Abel, T; Fehér, J	1
Aoki, K; Masuda, K; Miyazaki, T; Terauchi, Y; Togashi, Y	1
Garg, R; Hussey, C; Ibrahim, S	1
Baudrant, M; Benhamou, PY; Halimi, S; Lablanche, S; Skalli, S; Wion-Barbot, N	1
Unger, J	1
Kuritzky, L	1
Meier, JJ; Nauck, MA	1
Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P	1
Amatruda, JM; Arjona Ferreira, JC; Iwamoto, Y; Kadowaki, T; Nishii, M; Nonaka, K; Tajima, N; Taniguchi, T	1
Fakhoury, WK; Lereun, C; Wright, D	1
Brinker, A; Desai, S; Iyasu, S; Swann, J	1
Svec, F	1
Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N	1
Fernandes, R; Ferreira, L; Garrido, P; Mega, C; Melo, A; Nunes, S; Parada, B; Pinto, F; Pinto, R; Reis, F; Santos, P; Sereno, J; Teixeira, F; Teixeira-de-Lemos, E; Vala, H; Velada, I	1
Jackson, EK	1
Brown, NJ; Byrne, L; Kunchakarra, S; Marney, A	1
Chen, W; Garg, R; Pendergrass, M	1
Gerich, J	1
Bhalodia, Y; Manek, R; Sheth, N; Vaghasiya, J	1
Garber, AJ	1
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME	5
Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ	1
Opsteen, C; Qi, Y; Retnakaran, R; Vivero, E; Zinman, B	1
Alexander, CM; Cai, B; Girman, CJ; Katz, L; Williams-Herman, D	1
Caputo, S; Ghirlanda, G; Martini, F; Musella, T; Pitocco, D; Scavone, G; Zaccardi, F	1
Anjana, RM; Kishore, U; Mohan, V; Sudhakaran, C; Unnikrishnan, R	1
Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D	1
Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV	1
Hattori, S	1
Amatruda, JM; Golm, GT; Kaufman, KD; Meehan, AG; Shockey, GR; Steinberg, H; Teng, R; Thakkar, PR; Williams-Herman, DE; Yoon, KH	1
Acuña, C	1
Boudes, P; Viereck, C	1
Best, JH; Garrison, LP; Li, Y; Malloy, J; Peyrot, M; Rubin, RR; Yan, P	1
Desai, AA	1
Bergman, AJ; Chen, L; Davies, MJ; Gottesdiener, KM; Herman, GA; Langdon, RB; Larson, PJ; Mistry, GC; Ruckle, JL; Snyder, K; Wagner, JA; Wang, AQ; Yi, B; Zeng, W	1
Seyoum, B	1
Jellinger, PS	1
Ishiki, M; Ito, S; Mori, T; Nako, K; Ogawa, S; Okamura, M; Senda, M	1
Cuddihy, R; Davies, M; Hammer, M; Pratley, R; Thomsen, AB	1
Chwieduk, CM	1
Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV	1
Chen, B; Ernsberger, P; Escobedo, LV; Hou, D; Koletsky, MS; Koletsky, RJ; Moore, A	1
Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB	1
Hollingsworth, KG; Lim, EL; Smith, FE; Taylor, R; Thelwall, PE	1
Spellman, CW	1
Chen, M; Goldstein, BJ; Johnson-Levonas, AO; Kaufman, KD; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE	1
Amatruda, JM; Barzilai, N; Caporossi, S; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Langdon, RB; Mahoney, EM; Steinberg, H; Williams-Herman, D	1
Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P	1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A	1
Daniela, L; Ludvik, B	1
Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Seck, TL; Sisk, CM; Wang, H; Williams-Herman, DE	1
Hawkes, N	1
Matsuura, K; Mori, Y; Sezaki, K; Taniguchi, Y; Utsunomiya, K; Yokoyama, J	1
Hibi, T; Kaneko, F; Motoori, T; Oda, M; Ohbu, M; Shimizu, Y; Tahara, K; Takeuchi, H; Toyoda-Akui, M; Yokomori, H	1
Doggrell, SA	1
Chen, M; Goldstein, BJ; Kaufman, KD; Mehta, A; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE	1
Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R	1
Chisholm, DJ; Douglas, A; Greenfield, JR; Gribble, FM; Holst, JJ; Piyaratna, N; Samocha-Bonet, D; Synnott, EL; Wong, O	1
Kondo, M; Tanizawa, Y	1
Berg, JK; Gray, AL; Heilmann, CR; Holcombe, JH; Shenouda, SK	1
Hibi, H; Ohori, T; Yamada, Y	1
Kipnes, M; Subbarayan, S	1
Elahi, D; Meneilly, GS; Stafford, S	1
Gundert-Remy, U; Spranger, J; Stammschulte, T	1
Hurren, KM; Pinelli, NR	1
DeYoung, MB; Herbert, P; MacConell, L; Sarin, V; Trautmann, M	1
Fan, L; Gruenberger, JB; Kantor, E; Signorovitch, JE; Swallow, E; Wu, EQ	1
Engel, SS; Goldstein, BJ; Kaufman, KD; Lee, MA; Pérez-Monteverde, A; Seck, T; Sisk, CM; Williams-Herman, DE; Xu, L	1
Cander, S; Ersoy, C; Ertürk, E; Gül, CB; Imamoğlu, S; Kırhan, E; Kıyıcı, S; Öz, Ö; Sarandol, E; Sığırlı, D; Tuncel, E; Ünal, OK; Yorulmaz, H	1
Chubb, BD; Davies, MJ; Smith, IC; Valentine, WJ	1
Jermendy, G	2
Aoki, K; Kamiyama, H; Masuda, K; Shibuya, M; Terauchi, Y; Yoshimura, K	1
Akehi, Y; Kobayashi, K; Kodera, T; Kudo, T; Nagaishi, R; Nagasako, H; Nomiyama, T; Takenoshita, H; Terawaki, Y; Urata, H; Yanase, T	1
Al Elq, A; Al Omari, M; Al Sifri, S; Al Tayeb, K; Basiounny, A; Davies, MJ; Echtay, A; Engel, SS; Girman, CJ; Harman-Boehm, I; Kaddaha, G; Katzeff, HL; Mahfouz, AS; Musser, BJ; Ozesen, C; Radican, L; Suryawanshi, S	1
Ahn, HY; An, JH; Cho, YM; Choi, SH; Jang, HC; Kang, SM; Khang, AR; Lee, Y; Lim, S; Park, KS; Shin, H; Yoon, JW	1
Ogawa, Y; Shimada, S; Tanaka, K	1
Niessen, M; Spinas, GA; Xu, L	1
Davies, MJ; Goldstein, BJ; Golm, GT; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D; Xu, L	1
Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y	1
Hashimoto, K; Kumagai, C; Nishioka, T; Shinohara, M; Tanimoto, N	1
Engel, SS; Goldstein, BJ; Golm, GT; Hussain, S; Katz, L; Kaufman, KD; O'Neill, EA; Wainstein, J; Xu, L	1
Gerrald, KR; Jonas, DE; Runge, T; Van Scoyoc, E; Wines, RC	1
Aso, Y; Hara, K; Haruki, K; Inukai, T; Morita, K; Naruse, R; Ozeki, N; Shibazaki, M; Suetsugu, M; Takebayashi, K; Terasawa, T	1
Kato, T; Kono, S; Ohki, T; Sasaki, Y; Tajiri, Y; Tanaka, K; Tojikubo, M; Tsuruta, M; Yamada, K	1
Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B	1
Masmiquel Comas, L; Nicolau Ramis, J	1
Kishimoto, M; Noda, M	1
de Lemos, ET; Fernandes, R; Mascarenhas-Melo, F; Mega, C; Oliveira, J; Reis, F; Teixeira, F; Vala, H	1
Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM	1
Huh, JW; Jang, M; Kim, DH; Kim, TW; Park, JS; Suh, JH; Yoon, SY	1
Chen, W; Fenton, C; Haffner, SM; Pendergrass, M	1
Briand, F; Burcelin, R; Sulpice, T; Thieblemont, Q	1
Furukawa, S; Kumagi, T; Matsuura, B; Miyake, T; Murakami, M; Murakami, S; Niiya, T; Nishino, K; Onji, M; Ueda, T	1
Holst, JJ; Liu, MK; Salen, G; Saumoy, M; Shang, Q; Xu, G	1
Caminal-Montero, L; Coto-Segura, P; Esteve-Martinez, A; Mas-Vidal, A; Santos-Juanes, J	1
Gambale, JJ; Katz, LB; Rothenberg, PL; Sarich, TC; Stein, PP; Vaccaro, N; Vanapalli, SR; Xi, L	1
Best, JH; DeYoung, MB; Gaebler, JA; Guillermin, AL; Lloyd, A; Samyshkin, Y	1
Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB	1
Boddu, ND; Cheskin, LJ; Kahan, S; Kumar, AA; Palamaner Subash Shantha, G; Samson, RJ	1
Hood, AF; Litt, JZ; Rader, RK; Schuman, TP; Stoecker, WV; Stricklin, SM	1
Nauck, MA	1
Goldstein, BJ; Golm, GT; Kaufman, KD; Lee, M; O'Neill, EA; Steinberg, H; Teng, R; Yoon, KH	1
Davies, M; Speight, J	1
Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM	1
Rabasseda, X	1
Choi, SH; Hong, ES; Jang, HC; Kang, SM; Khang, AR; Lim, S; Park, KS; Shin, H; Walford, GA; Yoon, JW	1
Ahrén, B; Deacon, CF; Mannucci, E	1
Berman, S; Efrati, S; Golik, A; Hamad, RA; Koren, S; Peleg, RK; Shemesh-Bar, L; Tirosh, A; Vinker, S	1
Aono, M; Fukushima, T; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y	1
Lam, SY; Leung, KK; Leung, PS; Liang, J	1
Capuano, G; Nicolle, LE; Usiskin, K; Ways, K	1
Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B	1
Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W	1
Fukuda, K; Itoh, H; Kawai, T; Matsuhashi, T; Meguro, S; Mogi, S; Sano, M; Suzuki, Y	1
Nyirjesy, P; Usiskin, K; Ways, K; Zhao, Y	1
Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM	1
Burgmaier, M; Esser, M; Liberman, A; Ludwig, A; Marx, N; Ostertag, R; Vasic, D; Vittone, F; Walcher, D	1
Alba, M; Engel, SS; Goldstein, BJ; Guan, Y; Johnson-Levonas, AO; Kaufman, KD; Li, Z; Shentu, Y; Yang, W	1
Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D	1
Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E	1
Diamant, M	1
Firneisz, G; Somogyi, A	1
Alba, M; Astiarraga, B; Casolaro, A; Chen, Y; Ferrannini, E; Gastaldelli, A; Holst, J; Mari, A; Muscelli, E; Seghieri, G	1
Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR	2
Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D	1
Aso, Y	1
Aravind, SR; Balamurugan, R; Davies, MJ; Engel, SS; Girman, CJ; Gupta, JB; Ismail, SB; Katzeff, HL; Loh, SM; Radican, L; Suryawanshi, S; Wadhwa, T; Wolthers, T	1
Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE	1
Abuaysheh, S; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Green, K; Makdissi, A; Vora, M	1
Ishikawa, M; Yamada, Y	1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D	1
Ericsson, H; Hompesch, M; Knutsson, M; Leonsson-Zachrisson, M; Morrow, LA; Norjavaara, E; Wollbratt, M	1
Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S	1
Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P	1
Langer, J; Lee, WC; Palmer, JL; Samyshkin, Y	1
Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M	1
Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB	1
Buse, J; Jensen, KH; Niswender, K; Pi-Sunyer, X; Russell-Jones, D; Toft, AD; Zinman, B	1
Igaki, N; Yokota, K	1
Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K	1
Vella, A	1
Celikel, CA; Deyneli, O; Duman, DG; Kalayci, C; Yilmaz, Y; Yonal, O	1
Gahler, RJ; Grover, GJ; Juneja, P; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S	1
Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H	1
Liu, XL; Lü, XF; Shao, C; Wang, P; Xiao, XH; Xu, ZR; Yang, WY; Yang, ZJ	1
Denison, H; Eriksson, JW; Karlsson, C; Knutsson, M; Kujacic, M; Löfgren, L; Nilsson, C	1
Gupta, AK; Kailashiya, J; Kumar, N; Singh, SK; Verma, AK	1
Aono, M; Fujita, Y; Harashima, SI; Inagaki, N; Koizumi, T; Murata, Y; Ogura, M; Seike, M; Tanaka, D; Wang, Y; Yamane, S	1
Chen, M; Guo, Z; Hao, J; Houze, J; Lin, DC; Lopez, E; Luo, J; Ma, Z; Nguyen, K; Rulifson, IC; Tian, B; Tian, L; Tran, T; Wang, Y; Zhang, Y	1
Hansen, LS; Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS; Rosenkilde, MM; Viby, NE	1
Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K	1
Bianchi, L; Bonaventura, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D	1
Hasegawa, K; Iguchi, A; Kono, S; Nakagawachi, R; Odori, S; Sasaki, Y; Satoh-Asahara, N; Shimatsu, A; Tochiya, M; Wada, H	1
Drouet, C; Graffin, B; Hosotte, M; Kanny, G; Landy, C; Millot, I; Nadaud, J; Plancade, D; Ragot, C	1
Mateos, JL; Wajchenberg, BL	1
Aiello, R; Aspnes, GE; Atkinson, K; Baker, L; Barucci, N; Bian, J; Bourassa, P; Bourbonais, F; Bourbounais, F; D'Aquila, T; Derksen, DR; Filipski, KJ; Guzman-Perez, A; Hamilton, M; Hank, R; Jones, CS; Karki, K; Li, JC; Litchfield, J; MacDougall, M; Patel, L; Pfefferkorn, JA; Rasmusson, T; Robertson, A; Sammons, MF; Song, W; Tu, M; Zeng, D	1
Ikeda, T; Kirinoki-Ichikawa, S; Kubota, Y; Miyamoto, M; Mizuno, K; Takagi, G; Tanaka, K	1
Mahé, E; Sigal, ML; Sin, C	1
Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM	1
Devries, JH	1
Inazumi, T; Kimura, M; Komatsu, Y; Kondo, Y; Nakamura, A; Tajima, K; Takihata, M; Tamura, H; Terauchi, Y; Yamada, M; Yamazaki, S	1
Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Shapiro, D	1
Berry, D; Berry, S; Chien, J; Gaydos, B; Geiger, MJ; Skrivanek, Z	1
Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR	1
Brismar, K; Efendic, S; Hage, C; Lundman, P; Mellbin, L; Rydén, L	1
Arjona Ferreira, JC; Corry, D; Davies, MJ; Goldstein, BJ; Golm, GT; Gonzalez, EJ; Kaufman, KD; Mogensen, CE; Sloan, L; Xu, L	1
Bellon, M; Bound, MJ; Horowitz, M; Jones, KL; Rayner, CK; Standfield, SD; Wu, T; Zhao, BR	1
Baruah, MP; Chaudhury, T; Dharmalingam, M; Sethi, BK	1
Collet, P; Marotte, H; Nizeica, V	1
Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR	1
Kanamori, A; Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y	1
Akiyama, E; Fujisue, K; Hokimoto, S; Iwashita, S; Jinnouchi, H; Kaikita, K; Kurokawa, H; Maeda, H; Matsubara, J; Ogawa, H; Ohba, K; Sugiyama, S; Yamamoto, E	1
Satoh, K	1
Ida, K; Ikeda, H; Katsuno, T; Miyagawa, J; Namba, M	1
Bjerve, KS; Grill, VE; Mostad, IL; Qvigstad, E	1
Bax, JJ; Bountioukos, MA; Elhendy, A; Krenning, EP; Poldermans, D; Roelandt, JR; Schinkel, AF; Valkema, R; van Domburg, RT; Vourvouri, EC	1
Bajaj, M; Cusi, K; DeFronzo, RA; Kashyap, S; Mandarino, L; Suraamornkul, S	1
Bril, V; Buchanan, RA	2
Beconi, M; Eiermann, GJ; Fisher, MH; He, H; Hickey, GJ; Kim, D; Kowalchick, JE; Leiting, B; Lyons, K; Marsilio, F; McCann, ME; Patel, RA; Patel, SB; Petrov, A; Roy, RS; Scapin, G; Thornberry, NA; Wang, L; Weber, AE; Wu, JK; Wyvratt, MJ; Zhang, BB; Zhu, L	1
Gijsen, AP; Kaastra, B; Keizer, HA; Koopman, R; Manders, RJ; Saris, WH; Stegen, JH; van Loon, LJ	1
Dullaart, RP; Meinardi, JR; Riemens, SC; Sluiter, WJ; Wolffenbuttel, BH	1
Bajaj, M; Cline, GW; DeFronzo, RA; Mandarino, LJ; Romanelli, A; Shulman, GI; Suraamornkul, S	1
Bergman, AJ; Chen, L; Davies, MJ; De Smet, M; Herman, GA; Hilliard, D; Laethem, M; Ramael, S; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Wagner, JA; Wang, AQ; Winchell, G; Yi, B; Zeng, W; Zhou, Y	1
Heinzl, S	1
Feng, Y; Howard, AD; Li, C; Li, Z; Moller, DE; Mu, J; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E	1
Bergman, A; Cilissen, C; Davies, MJ; de Lepeleire, I; De Smet, M; Deacon, CF; Dietrich, B; Golor, G; Gottesdiener, KM; Herman, GA; Hilliard, D; Holst, JJ; Keymeulen, B; Kipnes, MS; Kotey, P; Lasseter, KC; Schrodter, A; Snyder, K; Stevens, C; Tanaka, W; Tanen, M; Van Dyck, K; Wagner, JA; Wang, AQ; Yi, B; Zeng, W; Zhao, P	1
Warpakowski, A	1
Caria, C; Hanefeld, M; Khatami, H; Raz, I; Williams-Herman, D; Xu, L	1
Bergman, A; Herman, GA; Kipnes, M; Yi, B	1
Biftu, T; Eiermann, G; Feng, D; Gao, YD; He, H; Kieczykowski, G; Leiting, B; Liang, GB; Lyons, K; Patel, S; Petrov, A; Qian, X; Scapin, G; Singh, S; Sinha-Roy, R; Thornberry, NA; Weber, AE; Wu, J; Zhang, B; Zhang, X	1
Barnett, A	1
Drucker, DJ; Nauck, MA	1
Traynor, K	1
Aschner, P; Kipnes, MS; Lunceford, JK; Mickel, C; Sanchez, M; Williams-Herman, DE	1
Charbonnel, B; Karasik, A; Liu, J; Meininger, G; Wu, M	1
Sanchez, M; Scott, R; Stein, P; Wu, M	1
Andryuk, PJ; Brazg, R; Lu, K; Rosenstock, J; Stein, P	1
Nathan, DM	1
Bajaj, M; Cersosimo, E; Cusi, K; Gastaldelli, A; Kashyap, S	1
Brazg, R; Cobelli, C; Dalla Man, C; Stein, PP; Thomas, K; Xu, L	1
Meininger, G; Nauck, MA; Sheng, D; Stein, PP; Terranella, L	1
Drucker, D; Easley, C; Kirkpatrick, P	1
Campbell, KM; Taylor, JR	1
Lyseng-Williamson, KA	1
Kipnes, MS	1
Raz, I	1
Thornberry, NA; Weber, AE	1
Deacon, CF	1
Winkler, G	1
Herman, GA; Stein, PP; Thornberry, NA; Wagner, JA	1
Pratley, RE; Salsali, A	1
Bergman, AJ; Cote, J; Gottesdiener, K; Herman, GA; Marbury, T; Smith, W; Swan, SK; Wagner, J; Yi, B	1
Feinglos, MN; Goldstein, BJ; Johnson, J; Lunceford, JK; Williams-Herman, DE	1
Bloomgarden, ZT; Inzucchi, SE	1
Mintz, ML	1
Irony, I; Meyer, RJ; Parks, MH	1
Eldor, R; Raz, I	1
Klein, HH; Meier, JJ; Schmidt, WE	1
Hanefeld, M; Herman, GA; Mickel, C; Sanchez, M; Stein, PP; Wu, M	1
Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P	1
Amori, RE; Lau, J; Pittas, AG	1
Jennings, HR; Langley, AK; Suffoletta, TJ	1
Whitehill, D	1
Mirza, SA	1
Dailey, GE	1
Heinzl, S; Musch, A	1
Ahmed, T; Davies, MJ; Fujimoto, G; Hirayama, Y; Kakikawa, T; Kato, N; Nonaka, K; Okuyama, K; Sato, A; Stein, PP; Suzuki, H	1
Perusicová, J	1
Aschner, P; Davies, MJ; Karasik, A; Katzeff, H; Stein, PP	1
Alba, M; Amatruda, JM; Chen, Y; Hussain, S; Kaufman, KD; Langdon, RB; Raz, I; Stein, PP; Wu, M	1
Davies, MJ; Engel, SS; Loeys, T; Scott, R	1
Pyon, EY; Zerilli, T	1
Nogid, A; Pham, DQ; Plakogiannis, R	1
Bandeira-Echtler, E; Bergerhoff, K; Lerch, CL; Richter, B	1
Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D	1
Charbonnel, B; Cobelli, C; Davies, MJ; Man, CD; Meninger, G; Stein, PP; Williams-Herman, D; Xu, L	1
Duh, D; Vandevijver, A	1
Erol, A	1
Choe, HM; Sweet, BV; VanDeKoppel, S	1
Beyer, KH; Chambers, CE; Demers, LM; Passananti, GT; Seaton, TD; Vesell, ES	1
Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW	1
Beck-Nielsen, H; Henriksen, JE; Melander, A; Thye-Rønn, P; Vaag, A; Worm, D	1
Bergman, J; Haaparanta, M; Härkönen, R; Hartiala, J; Knuuti, MJ; Mäki, M; Nuutila, P; Ruotsalainen, U; Teräs, M; Voipio-Pulkki, LM; Wegelius, U; Yki-Järvinen, H	1
Beyer, KH; Chambers, CE; Demers, LM; Passananti, GT; Vesell, ES	1
Puhakainen, I; Yki-Järvinen, H	1
Ekstrand, A; Eriksson, J; Franssila-Kallunki, A; Groop, L; Saloranta, C; Taskinen, MR	1
Babic, D; Cvrkalová, AL; Klimes, I; Koev, D; Langrová, H; Profozic, V; Rajecová, E; Skrabalo, Z; Susic, M; Zlateva, S	1
Groop, L; Härkönen, M; Melander, A; Saloranta, C; Taskinen, MR; Widen, E	1
Balogh, Z; Boda, J; Juhász, A; Leövey, A; Mohácsi, A; Paragh, G	1
Alberti, KG; Berrish, TS; Cooper, BG; Elliott, C; Orskov, H; Reed, JW; Walker, M	1
Alberti, KG; Farrer, M; Fulcher, GR; Johnson, AS; Walker, M	1
Akanji, AO; Hockaday, TD; Kirk, M; Osifo, E	1
Agius, L; Alberti, KG; Orskov, H; Walker, M	1
Alberti, KG; Brown, MD; Conti, M; Davis, SN; Monti, LD; Piatti, PM; Pozza, G	1
Liang, J; Yu, Y; Zhang, X	1
Groop, L; Saloranta, C	1
Ho, LT; Hsiao, LC; Hwu, CM; Kwok, CF; Li, SH; Liu, YF; Shih, KC	1
D'Onofrio, F; Gambardella, A; Gentile, S; Gualdiero, P; Manzella, D; Paolisso, G; Rizzo, MR; Tagliamonte, MR; Varricchio, M; Verza, M	1
Balogh, Z; Boda, J; Kárpáti, L; Kovács, P; Leövey, A; Paragh, G; Szabó, J	1
Alberti, KG; Davoren, PM; Gries, FA; Hubinger, A; Kelly, W; Whately-Smith, C	1
D'Onofrio, F; Gambardella, A; Giugliano, D; Gualdiero, P; Howard, BV; Paolisso, G; Rizzo, MR; Saccomanno, F; Tagliamonte, MR	1
Chan, DC; Chow, CC; Cockram, CS; Ko, GT; Lam, CW; Mak, TW; Tsang, LW; Yeung, VT	1
Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD	1
Dullaart, RP; Riemens, SC; Sluiter, WJ; van Tol, A	1
Baum, RP; Hertel, A; Hör, G; Schröder, O	1
Beyer, KH; Vesell, ES	1
Beck-Nielsen, H; Henriksen, JE; Vaag, A; Vinten, J; Worm, D	1
Ackermans, MT; Endert, E; Romijn, JA; Sauerwein, HP; Sprangers, F	1
Dullaart, RP; van Tol, A	1
Alberti, KG; Catalano, C; Farrer, M; Fulcher, GR; Walker, M	1
Agius, L; Alberti, KG; Catalano, C; Fulcher, GR; Walker, M	1
Beck-Nielsen, H; Vaag, AA	1
Alberti, KG; Catalano, C; Farrer, M; Fulcher, GR; Thow, J; Walker, M; Whately-Smith, CR	1
Cvrkalová, A; Hanzen, E; Klimes, I; Kréze, A; Lacko, A; Langrová, H; Rajecová, E	1
Ekstrand, A; Franssila-Kallunki, A; Groop, L; Saloranta, C; Taskinen, MR	1
Beck-Nielsen, H; Damsbo, P; Gall, MA; Richter, EA; Skött, P; Vaag, A	1
Bain, SC; Barnett, AH; Jones, AF	1

Reviews

128 review(s) available for pyrazines and Diabetes Mellitus, Type 2

Article	Year
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. Journal of diabetes, 2013, Volume: 5, Issue:3 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Molecular Structure; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms	2013
Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. Journal of evidence-based medicine, 2012, Volume: 5, Issue:3 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hospital practice (1995), 2013, Volume: 41, Issue:2 Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgraduate medicine, 2013, Volume: 125, Issue:3 Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jul-01, Volume: 70, Issue:13 Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms	2013
Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Current medical research and opinion, 2013, Volume: 29, Issue:11 Topics: Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. Drug design, development and therapy, 2013, Volume: 7 Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Triazoles	2013
Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis. PloS one, 2013, Volume: 8, Issue:10 Topics: Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Metformin; Outcome Assessment, Health Care; Pioglitazone; Proinsulin; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2013
Hyperammonemia, resolved by chemotherapy. Annals of hematology, 2014, Volume: 93, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Coma; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Humans; Hyperammonemia; Paraproteinemias; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Respiration, Artificial	2014
Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs, 2014, Volume: 74, Issue:2 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139 Suppl 2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult	2014
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Advances in therapy, 2014, Volume: 31, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss	2014
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin	2014
Clinical review of sitagliptin: a DPP-4 inhibitor. The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:9 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work. Allergology international : official journal of the Japanese Society of Allergology, 2014, Volume: 63, Issue:3 Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Eruptions; Female; Humans; Hypersensitivity, Delayed; Hypoglycemic Agents; Immunologic Tests; Lymphocyte Activation; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Skin; Triazoles; Withholding Treatment	2014
Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PloS one, 2014, Volume: 9, Issue:8 Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Lipids; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgraduate medicine, 2014, Volume: 126, Issue:6 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2014
Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. Drug design, development and therapy, 2014, Volume: 8 Topics: Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycemic Agents; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Triazoles	2014
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3 Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2015
Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics. Vascular health and risk management, 2015, Volume: 11 Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemia; Polypharmacy; Pyrazines; Risk Factors; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain	2015
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin. Postgraduate medicine, 2015, Volume: 127, Issue:3 Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss	2015
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials. Clinical therapeutics, 2015, May-01, Volume: 37, Issue:5 Topics: Blood Pressure; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles	2015
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Frontiers in bioscience : a journal and virtual library, 2008, May-01, Volume: 13 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
[New drugs; exenatide and sitagliptin]. Nederlands tijdschrift voor geneeskunde, 2008, Apr-12, Volume: 152, Issue:15 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2008
New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:9 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2008
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current opinion in clinical nutrition and metabolic care, 2008, Volume: 11, Issue:4 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vascular health and risk management, 2008, Volume: 4, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2008
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:10 Topics: Adult; Aged; Blood Pressure; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Pregnancy; Pyrazines; Sitagliptin Phosphate; Triazoles	2008
Drugs for type 2 diabetes. Treatment guidelines from the Medical Letter, 2008, Volume: 6, Issue:71 Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles	2008
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Current opinion in drug discovery & development, 2008, Volume: 11, Issue:4 Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin	2008
New treatments for type 2 diabetes--the DPP4 inhibitors. Primary care diabetes, 2007, Volume: 1, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
DPP4 inhibitors: a new approach in diabetes treatment. Advances in therapy, 2008, Volume: 25, Issue:7 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. The AAPS journal, 2008, Volume: 10, Issue:2 Topics: Animals; Biomarkers; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2008
Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles	2008
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:43 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes research and clinical practice, 2008, Dec-15, Volume: 82 Suppl 2 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vascular health and risk management, 2008, Volume: 4, Issue:4 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2008
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vascular health and risk management, 2008, Volume: 4, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2008
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh medical journal : MMJ, 2009, Volume: 18, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Advances in therapy, 2009, Volume: 26, Issue:3 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil	2009
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta bio-medica : Atenei Parmensis, 2008, Volume: 79, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Impact of sitagliptin on markers of beta-cell function: a meta-analysis. The American journal of the medical sciences, 2009, Volume: 337, Issue:5 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Homeostasis; Humans; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Placebos; Proinsulin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2009
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin	2008
[The value of incretin based therapies]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:8 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:11 Topics: Bayes Theorem; Confidence Intervals; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2009
Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Current medicinal chemistry, 2009, Volume: 16, Issue:23 Topics: Diabetes Mellitus, Type 2; Dimerization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycosylation; Humans; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2009
Defining the importance of daily glycemic control and implications for type 2 diabetes management. Postgraduate medicine, 2009, Volume: 121, Issue:5 Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles	2009
DPP-4 inhibitors in clinical practice. Postgraduate medicine, 2009, Volume: 121, Issue:6 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 5 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms	2009
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. Pharmazie in unserer Zeit, 2010, Volume: 39, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs, 2010, Mar-05, Volume: 70, Issue:4 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
Incretin-based therapies: review of current clinical trial data. The American journal of medicine, 2010, Volume: 123, Issue:3 Suppl Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]. Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2010
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus]. Medizinische Klinik (Munich, Germany : 1983), 2010, Volume: 105, Issue:3 Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss	2010
The physiologic role of incretin hormones: clinical applications. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil	2010
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. International journal of clinical practice, 2010, Volume: 64, Issue:7 Topics: Acute Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatitis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Triazoles	2010
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. Orvosi hetilap, 2010, Jun-20, Volume: 151, Issue:25 Topics: Administration, Oral; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
Managing type 2 diabetes in the primary care setting: beyond glucocentricity. The American journal of the medical sciences, 2010, Volume: 340, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2010
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology, 2010, Volume: 86, Issue:1 Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss	2010
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:8 Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2010
Incretin physiology and its role in type 2 diabetes mellitus. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2010
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:36 Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin	2010
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clinical pharmacokinetics, 2010, Volume: 49, Issue:9 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:10 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
DPP-4 inhibitors: what may be the clinical differentiators? Diabetes research and clinical practice, 2010, Volume: 90, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. The American journal of managed care, 2010, Volume: 16, Issue:7 Suppl Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors]. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46 Suppl F Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
Sitagliptin and metformin--novel combination therapy. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgraduate medicine, 2011, Volume: 123, Issue:1 Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2011
Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs, 2011, Feb-12, Volume: 71, Issue:3 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients. The Journal of the American Osteopathic Association, 2011, Volume: 111, Issue:2 Suppl 1 Topics: Algorithms; Chronic Disease; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2011
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital practice (1995), 2011, Volume: 39, Issue:1 Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin	2011
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:13 Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms	2011
Sitagliptin: a review. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:10 Topics: Administration, Oral; Algorithms; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:7-8 Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2011
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes technology & therapeutics, 2011, Volume: 13, Issue:11 Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Lactic Acid; Peptides; Pioglitazone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2011
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]. Orvosi hetilap, 2011, Sep-11, Volume: 152, Issue:37 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin	2011
[Incretin-based therapy for treating patients with type 2 diabetes]. Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48 Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin	2011
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes & metabolism, 2012, Volume: 38, Issue:2 Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain	2012
Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. Endocrine journal, 2012, Volume: 59, Issue:4 Topics: Aged, 80 and over; Biguanides; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Overdose; Female; Glucose; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Suicide, Attempted; Sulfonylurea Compounds; Triazoles	2012
The design of the liraglutide clinical trial programme. Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 2 Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms	2012
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Medication Adherence; Patient Satisfaction; Peptides; Pyrazines; Self Care; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles; Venoms; Weight Loss	2012
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. Current diabetes reviews, 2012, Volume: 8, Issue:3 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:8 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Male; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms	2012
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:6 Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
[Liraglutide: new results in the treatment of type 2 diabetes mellitus]. Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48 Suppl B Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2012
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular diabetology, 2013, Jan-03, Volume: 12 Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Young Adult	2013
Liraglutide in type 2 diabetes mellitus. Journal of the Indian Medical Association, 2012, Volume: 110, Issue:5 Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2012
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:3 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International journal of clinical practice, 2006, Volume: 60, Issue:11 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Models, Animal; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England), 2006, Nov-11, Volume: 368, Issue:9548 Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diabetes & vascular disease research, 2006, Volume: 3, Issue:3 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:1 Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes care, 2007, Volume: 30, Issue:6 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
Diabetes drug update: how 4 new options stack up. The Journal of family practice, 2007, Volume: 56, Issue:3 Topics: Administration, Inhalation; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Exenatide; Family Practice; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Islet Amyloid Polypeptide; Male; Peptides; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms	2007
Sitagliptin. Drugs, 2007, Volume: 67, Issue:4 Topics: Adenosine Deaminase Inhibitors; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Current topics in medicinal chemistry, 2007, Volume: 7, Issue:6 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prodrugs; Pyrazines; Serine Proteinase Inhibitors; Sitagliptin Phosphate; Triazoles	2007
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:4 Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. Orvosi hetilap, 2007, Apr-01, Volume: 148, Issue:13 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:5 Topics: Animals; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Resistance; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
[New concepts in the treatment of type 2 diabetes]. Der Internist, 2007, Volume: 48, Issue:7 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vascular health and risk management, 2007, Volume: 3, Issue:2 Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoproteins; Humans; Isoenzymes; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007, Jul-11, Volume: 298, Issue:2 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy, 2007, Volume: 27, Issue:8 Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
Using prandial insulin to achieve glycemic control in type 2 diabetes. The Journal of family practice, 2007, Volume: 56, Issue:9 Topics: Algorithms; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Postprandial Period; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms	2007
[Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2]. Medizinische Monatsschrift fur Pharmazeuten, 2007, Volume: 30, Issue:8 Topics: Adenosine Deaminase Inhibitors; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2007
DPP-4 inhibitors. Best practice & research. Clinical endocrinology & metabolism, 2007, Volume: 21, Issue:4 Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin	2007
[Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin]. Vnitrni lekarstvi, 2007, Volume: 53, Issue:10 Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Current diabetes reports, 2007, Volume: 7, Issue:5 Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:11 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Current medical research and opinion, 2008, Volume: 24, Issue:2 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2008
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clinical therapeutics, 2007, Volume: 29, Issue:12 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Molecular Structure; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Mar-15, Volume: 65, Issue:6 Topics: Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2008
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:12 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2008
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting	2008
Managed care perspective on three new agents for type 2 diabetes. Journal of managed care pharmacy : JMCP, 2008, Volume: 14, Issue:4 Topics: Amyloid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Managed Care Programs; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms	2008
[Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia]. Orvosi hetilap, 1993, Jan-17, Volume: 134, Issue:3 Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines	1993
Interactions between glucose and FFA metabolism in man. Diabetes/metabolism reviews, 1996, Volume: 12, Issue:1 Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipolysis; Models, Biological; Niacin; Obesity; Pyrazines	1996
Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus. Toxicology, 2000, Apr-03, Volume: 144, Issue:1-3 Topics: Animals; Antihypertensive Agents; Biological Transport, Active; Diabetes Mellitus, Type 2; Guanidines; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Kidney Diseases; Pyrazines; Rats	2000

Trials

222 trial(s) available for pyrazines and Diabetes Mellitus, Type 2

Article	Year
ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19. BMJ open, 2021, 12-01, Volume: 11, Issue:12 Topics: Azetidines; Clinical Trials, Phase II as Topic; COVID-19; Diabetes Mellitus, Type 2; Humans; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; State Medicine; Treatment Outcome	2021
Adipose tissue lipolytic inhibition enhances the glucoregulatory properties of exercise in type 2 diabetes patients. European journal of sport science, 2018, Volume: 18, Issue:9 Topics: Adipose Tissue; Administration, Oral; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Fatty Acids; Glycogen; Humans; Hypolipidemic Agents; Insulin; Lactic Acid; Lipid Metabolism; Male; Middle Aged; Pyrazines; Triglycerides	2018
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy. Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:7 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2013
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2013
Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clinical therapeutics, 2013, Volume: 35, Issue:3 Topics: Animals; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Glucagon-Like Peptide 1; Glycosides; Humans; Hypoglycemic Agents; Mice; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Triazoles	2013
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug design, development and therapy, 2013, Volume: 7 Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2013
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:8 Topics: Analysis of Variance; Azetidines; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Enzyme Activation; Enzyme Reactivators; Europe; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Time Factors; Treatment Outcome; Triglycerides	2013
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:4 Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2013
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10 Topics: Asian People; Azetidines; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Pyrazines; Time Factors; Treatment Outcome	2013
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. Journal of the American Heart Association, 2013, Jan-28, Volume: 2, Issue:1 Topics: Adult; Aged; Biomarkers; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol; Japan; Linear Models; Male; Middle Aged; Piperidines; Prospective Studies; Pyrazines; Regional Blood Flow; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Uracil; Vasodilation	2013
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes care, 2013, Volume: 36, Issue:9 Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles	2013
Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus. Endocrine journal, 2013, Volume: 60, Issue:7 Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:8 Topics: Administration, Oral; Argentina; Blood Glucose; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; India; Insulin, Long-Acting; Male; Mexico; Middle Aged; Pyrazines; Sitagliptin Phosphate; South Africa; Treatment Outcome; Triazoles; Turkey; United States	2013
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Diabetes care, 2013, Volume: 36, Issue:9 Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri Diabetologia, 2013, Volume: 56, Issue:7 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult	2013
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes care, 2013, Volume: 36, Issue:8 Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2013
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. Postgraduate medicine, 2013, Volume: 125, Issue:3 Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms	2013
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12 Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Middle Aged; Pioglitazone; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2013
Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes care, 2013, Volume: 36, Issue:11 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inpatients; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2014
Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocrine journal, 2013, Volume: 60, Issue:10 Topics: Aged; Asian People; Blood Glucose; Blood Glucose Self-Monitoring; Body Mass Index; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia, 2013, Volume: 56, Issue:12 Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles	2013
A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:10 Topics: Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxidative Stress; Patient Compliance; Prospective Studies; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2013
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Current medical research and opinion, 2014, Volume: 30, Issue:2 Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss	2014
Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:17 Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Inositol; Insulin; Isoindoles; Male; Middle Aged; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles	2013
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:19 Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inflammation Mediators; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:4 Topics: Acetates; Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Diarrhea; Dose-Response Relationship, Drug; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Male; Middle Aged; Obesity; Peptide YY; Pyrazines; Treatment Outcome; Weight Loss	2014
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes care, 2014, Volume: 37, Issue:3 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss	2014
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes, 2014, Volume: 63, Issue:2 Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucose; Humans; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes care, 2013, Volume: 36, Issue:12 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2013
DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocrine journal, 2014, Volume: 61, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Chemokine CXCL12; Cross-Over Studies; Cyclic AMP; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Piperidines; Pyrazines; Receptor, Angiotensin, Type 1; Sitagliptin Phosphate; Triazoles; Up-Regulation; Uracil	2014
Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. Advances in therapy, 2013, Volume: 30, Issue:11 Topics: Administration, Oral; Adult; Aged; Blood Glucose; Confidence Intervals; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Postprandial Period; Prospective Studies; Pyrazines; Reference Values; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2013
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American heart journal, 2013, Volume: 166, Issue:6 Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles	2013
Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes, 2014, Volume: 63, Issue:3 Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Gastric Emptying; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Secretion; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles	2014
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. European journal of endocrinology, 2014, Volume: 170, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucocorticoids; Glucose Intolerance; Humans; Insulin Resistance; Islets of Langerhans; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prednisolone; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:8 Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2014
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circulation. Cardiovascular imaging, 2014, Volume: 7, Issue:2 Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Doppler; Echocardiography, Stress; Electrocardiography; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Heart Ventricles; Humans; Male; Myocardial Ischemia; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left	2014
Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs & aging, 2014, Volume: 31, Issue:3 Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. The American journal of managed care, 2014, Volume: 20, Issue:1 Suppl Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles	2014
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study. Diabetes technology & therapeutics, 2014, Volume: 16, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5 Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss	2014
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients. Metabolism: clinical and experimental, 2014, Volume: 63, Issue:6 Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1	2014
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia, 2014, Volume: 57, Issue:5 Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles	2014
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes. Medical archives (Sarajevo, Bosnia and Herzegovina), 2013, Volume: 67, Issue:5 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides	2013
Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes. Endocrine journal, 2014, Volume: 61, Issue:5 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infusions, Subcutaneous; Insulin; Insulin Infusion Systems; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Diabetes & endocrinology, 2013, Volume: 1, Issue:3 Topics: Analysis of Variance; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles	2013
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes, 2014, Volume: 63, Issue:8 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PloS one, 2014, Volume: 9, Issue:4 Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles	2014
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes care, 2014, Volume: 37, Issue:7 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazines; Triazoles	2014
Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles	2014
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study. International journal of cardiology, 2014, Jun-15, Volume: 174, Issue:2 Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prospective Studies; Pyrazines; Research Design; Sitagliptin Phosphate; Triazoles	2014
Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:10 Topics: Acarbose; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Male; Middle Aged; Prospective Studies; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles	2014
A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study. Cardiovascular diabetology, 2014, May-24, Volume: 13 Topics: Adiponectin; Aged; Asian People; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2014
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2014
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:11 Topics: Azetidines; Blood Glucose; Body Mass Index; Catecholamines; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Activators; Fasting; Female; Glucagon; Glucokinase; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines	2014
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgraduate medicine, 2014, Volume: 126, Issue:3 Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss	2014
Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. The American journal of cardiology, 2014, Aug-01, Volume: 114, Issue:3 Topics: Aged; Aged, 80 and over; Blood Glucose; Carotid Arteries; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Tunica Intima; Ultrasonography	2014
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus. Arquivos brasileiros de endocrinologia e metabologia, 2014, Volume: 58, Issue:4 Topics: Activation, Metabolic; Adult; Alanine Transaminase; Area Under Curve; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Evoked Potentials, Somatosensory; Fasting; Female; Food, Formulated; gamma-Glutamyltransferase; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles; Triglycerides	2014
Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin. Diabetes technology & therapeutics, 2014, Volume: 16, Issue:10 Topics: Adult; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2014
Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes. Diabetes care, 2014, Volume: 37, Issue:9 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Venoms; Young Adult	2014
Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism: clinical and experimental, 2014, Volume: 63, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cell Adhesion Molecules; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Phospholipases A2, Secretory; Pyrazines; Sitagliptin Phosphate; Solubility; Triazoles	2014
The amino acid response to a mixed meal in patients with type 2 diabetes: effect of sitagliptin treatment. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:11 Topics: Adult; Aged; Amino Acids; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Humans; Hydroxybutyrates; Insulin; Insulin Resistance; Male; Meals; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes care, 2014, Volume: 37, Issue:10 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Receptors, Glucagon; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:12 Topics: Apolipoprotein B-48; Apolipoproteins; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides	2014
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovascular diabetology, 2014, Jul-30, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycoside Hydrolase Inhibitors; Humans; Inositol; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult	2014
Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus. Clinical and investigative medicine. Medecine clinique et experimentale, 2014, Aug-01, Volume: 37, Issue:4 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Malondialdehyde; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Endocrine journal, 2014, Volume: 61, Issue:12 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Japan; Kidney; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2014
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1 Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation	2015
[Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus]. Terapevticheskii arkhiv, 2014, Volume: 86, Issue:8 Topics: Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:17 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Middle Aged; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes, 2015, Volume: 64, Issue:4 Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Pyrazines	2015
The durability of sitagliptin in elderly patients with type 2 diabetes. Clinical interventions in aging, 2014, Volume: 9 Topics: Aged; Blood Glucose; Body Mass Index; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Diagnostic Techniques, Ophthalmological; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Urinalysis	2014
Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial". Diabetes research and clinical practice, 2014, Volume: 106, Issue:3 Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incretins; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2014
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. The American journal of managed care, 2014, Volume: 20, Issue:13 Suppl Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles	2014
More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods. Current computer-aided drug design, 2014, Volume: 10, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Female; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Male; Middle Aged; Models, Molecular; Pyrazines; Quantitative Structure-Activity Relationship; Romania; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8 Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Postprandial Period; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles	2015
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2015, Jul-16, Volume: 373, Issue:3 Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Heart Diseases; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles	2015
Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:3 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glucose Tolerance Test; Glucosides; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Young Adult	2016
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study. Journal of diabetes research, 2016, Volume: 2016 Topics: Administration, Oral; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Japan; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Motor Neurons; Neural Conduction; Pyrazines; Sensory Receptor Cells; Severity of Illness Index; Spiro Compounds; Temperature	2016
Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:5 Topics: Adipose Tissue; Aged; Austria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Down-Regulation; Energy Metabolism; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Lipolysis; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Proton Magnetic Resonance Spectroscopy; Pyrazines; Risk Factors; Single-Blind Method; Stroke Volume; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left	2016
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:7 Topics: Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Placebos; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2008
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Current medical research and opinion, 2008, Volume: 24, Issue:10 Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms	2008
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes research and clinical practice, 2009, Volume: 83, Issue:1 Topics: Adult; Aged; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; India; Korea; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2009,Winter, Volume: 16, Issue:1 Topics: Administration, Oral; Aged; Area Under Curve; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Half-Life; Hepatic Insufficiency; Humans; Liver Function Tests; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles	2009
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Current medical research and opinion, 2009, Volume: 25, Issue:3 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2009, Volume: 41, Issue:3 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Middle Aged; Patient Selection; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles; Young Adult	2009
Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes care, 2009, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Median Nerve; Middle Aged; Motor Neurons; Neural Conduction; Placebos; Pyrazines; Sensory Thresholds; Spiro Compounds; Sural Nerve; Young Adult	2009
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:8 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Current medical research and opinion, 2009, Volume: 25, Issue:10 Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2009
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism: clinical and experimental, 2010, Volume: 59, Issue:6 Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha	2010
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:3 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult	2010
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:2 Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocrine journal, 2010, Volume: 57, Issue:5 Topics: Adult; Aged; Area Under Curve; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult	2010
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes care, 2010, Volume: 33, Issue:7 Topics: Administration, Oral; Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelial Cells; Enzyme Activation; Female; Hematopoietic Stem Cells; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pilot Projects; Pyrazines; Receptors, CXCR4; Sitagliptin Phosphate; Triazoles	2010
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:4 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. Revue medicale de Liege, 2010, Volume: 65, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Belgium; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:5 Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet (London, England), 2010, Apr-24, Volume: 375, Issue:9724 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Triazoles; Young Adult	2010
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. International journal of clinical practice, 2010, Volume: 64, Issue:5 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult	2010
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocrine journal, 2010, Volume: 57, Issue:8 Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Food; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Insulin; Kinetics; Male; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet (London, England), 2010, Aug-07, Volume: 376, Issue:9739 Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2010
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:7 Topics: Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 56, Issue:4 Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Hemodynamics; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Pyrazines; Renal Circulation; Sitagliptin Phosphate; Sodium; Triazoles	2010
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/metabolism research and reviews, 2010, Volume: 26, Issue:7 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:10 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pilot Projects; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:2 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2011
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:3 Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss	2011
Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocrine journal, 2011, Volume: 58, Issue:1 Topics: Albuminuria; Anti-Inflammatory Agents; Blood Pressure; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. International journal of clinical practice, 2011, Volume: 65, Issue:2 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2011
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes care, 2011, Volume: 34, Issue:2 Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Health Status; Humans; Hypoglycemic Agents; Male; Mental Health; Middle Aged; Patient Satisfaction; Peptides; Pioglitazone; Pyrazines; Quality of Life; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms	2011
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British journal of clinical pharmacology, 2011, Volume: 71, Issue:3 Topics: Administration, Oral; Adult; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Research Design; Sitagliptin Phosphate; Statistics as Topic; Triazoles; Young Adult	2011
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. The Tohoku journal of experimental medicine, 2011, Volume: 223, Issue:2 Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypertension; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2011
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles	2011
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss	2011
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:7 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult	2011
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Current medical research and opinion, 2011, Volume: 27, Issue:5 Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Male; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles	2011
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:6 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms	2011
[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care]. Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:7-8 Topics: Austria; Diabetes Mellitus, Type 2; Drug Tolerance; Female; Humans; Male; Metformin; Middle Aged; Prevalence; Primary Health Care; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2011
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes research and clinical practice, 2011, Volume: 93, Issue:1 Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain	2011
Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes technology & therapeutics, 2011, Volume: 13, Issue:7 Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:9 Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult	2011
The metabolic syndrome influences the response to incretin-based therapies. Acta diabetologica, 2011, Volume: 48, Issue:3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2011
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. The Journal of nutrition, 2011, Volume: 141, Issue:7 Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glutamine; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:11 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms; Young Adult	2011
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. Journal of the American Geriatrics Society, 2011, Volume: 59, Issue:6 Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Insulin; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2011
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes. International journal of clinical practice, 2011, Volume: 65, Issue:9 Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult	2011
Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes. Diabetes research and clinical practice, 2011, Volume: 94, Issue:2 Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Female; Ghrelin; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Turkey	2011
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta diabetologica, 2012, Volume: 49, Issue:3 Topics: 1-Deoxynojirimycin; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Food-Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes research and clinical practice, 2012, Volume: 95, Issue:2 Topics: Adult; Aged; Asia; Asian People; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. International journal of clinical practice, 2011, Volume: 65, Issue:11 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Islam; Male; Middle Aged; Middle East; Pyrazines; Residence Characteristics; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Young Adult	2011
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clinical endocrinology, 2012, Volume: 77, Issue:2 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:1 Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult	2012
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes care, 2012, Volume: 35, Issue:2 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms	2012
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:8 Topics: Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Middle Aged; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:11 Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms	2012
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:8 Topics: Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2012
Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:9 Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Waist Circumference	2012
The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes technology & therapeutics, 2012, Volume: 14, Issue:7 Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Stiffness; Young Adult	2012
Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. International journal of clinical practice, 2012, Volume: 66, Issue:5 Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2012
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Current medical research and opinion, 2012, Volume: 28, Issue:7 Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections	2012
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10 Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles	2012
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Current medical research and opinion, 2012, Volume: 28, Issue:7 Topics: Antifungal Agents; Blood Glucose; Canagliflozin; Candida; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Vagina	2012
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. Journal of diabetes, 2012, Volume: 4, Issue:3 Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes research and clinical practice, 2012, Volume: 98, Issue:1 Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet (London, England), 2012, Jun-16, Volume: 379, Issue:9833 Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:8 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes care, 2012, Volume: 35, Issue:10 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2012
Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Current medical research and opinion, 2012, Volume: 28, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemia; Hypoglycemic Agents; India; Islam; Malaysia; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Young Adult	2012
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. Journal of diabetes, 2013, Volume: 5, Issue:1 Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2013
Sitagliptin exerts an antinflammatory action. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blotting, Western; C-Reactive Protein; Cell Separation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; I-kappa B Kinase; Interleukin-6; Male; MAP Kinase Kinase 4; Middle Aged; Monocytes; Prospective Studies; Pyrazines; Receptors, CCR2; Sitagliptin Phosphate; Toll-Like Receptor 2; Toll-Like Receptor 4; Triazoles; Tumor Necrosis Factor-alpha	2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10 Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2012
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:12 Topics: Adult; Azetidines; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Peptide Fragments; Pyrazines; Single-Blind Method; Treatment Outcome	2012
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. The Journal of the Association of Physicians of India, 2012, Volume: 60 Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles	2012
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes & metabolism, 2012, Volume: 38, Issue:4 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult	2012
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes care, 2012, Volume: 35, Issue:10 Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:1 Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Weight Loss	2013
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovascular diabetology, 2012, Aug-06, Volume: 11 Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2012
[Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China]. Zhonghua yi xue za zhi, 2012, Jun-12, Volume: 92, Issue:22 Topics: Adult; Aged; Aged, 80 and over; China; Chromium; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Picolinic Acids; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:2 Topics: Acetates; Adult; Area Under Curve; Cohort Studies; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Diglycerides; Dose-Response Relationship, Drug; Humans; Insulin Resistance; Intestinal Absorption; Male; Mass Spectrometry; Postprandial Period; Pyrazines; Treatment Outcome; Triglycerides	2013
Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2013, Volume: 45, Issue:3 Topics: Aged; Asian People; Body Mass Index; Body Weight; C-Peptide; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Pyrazines; ROC Curve; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2013
Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundamental & clinical pharmacology, 2014, Volume: 28, Issue:2 Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Lipids; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:17 Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism: clinical and experimental, 2013, Volume: 62, Issue:3 Topics: Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Inflammation; Interleukin-10; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrazines; Regression Analysis; Serum Amyloid A Protein; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha	2013
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. Journal of Korean medical science, 2012, Volume: 27, Issue:11 Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Nitroglycerin; Prospective Studies; Pyrazines; Regression Analysis; Sitagliptin Phosphate; Triazoles; Vasodilation; Vasodilator Agents	2012
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes care, 2013, Volume: 36, Issue:5 Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles	2013
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:5 Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles	2013
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. Journal of diabetes science and technology, 2012, Nov-01, Volume: 6, Issue:6 Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Research Design; Sitagliptin Phosphate; Triazoles	2012
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2013
Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study. Journal of internal medicine, 2013, Volume: 273, Issue:4 Topics: Acute Coronary Syndrome; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2013
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013, Volume: 61, Issue:4 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Pyrazines; Renal Dialysis; Sitagliptin Phosphate; Triazoles	2013
Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes care, 2013, Volume: 36, Issue:7 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Postprandial Period; Pyrazines; Radioimmunoassay; Sitagliptin Phosphate; Triazoles; Xylose	2013
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis, 2013, Volume: 227, Issue:2 Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin	2013
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, Volume: 44, Issue:6 Topics: Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Male; Middle Aged; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Ventricular Dysfunction, Left	2003
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes care, 2004, Volume: 27, Issue:10 Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electromyography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Probability; Pyrazines; Reference Values; Risk Assessment; Severity of Illness Index; Spiro Compounds; Sural Nerve; Treatment Outcome	2004
Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic patients. Diabetologia, 2005, Volume: 48, Issue:10 Topics: Adipose Tissue; Aged; Algorithms; Body Composition; Body Mass Index; Breath Tests; Diabetes Mellitus, Type 2; Diet; Energy Metabolism; Exercise Test; Fatty Acids, Nonesterified; Female; Glycogen; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipolysis; Male; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Palmitates; Pyrazines	2005
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes, 2005, Volume: 54, Issue:11 Topics: Acyl Coenzyme A; Adiponectin; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Male; Middle Aged; Muscle, Skeletal; Pyrazines	2005
Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes care, 2006, Volume: 29, Issue:1 Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Motor Neurons; Neural Conduction; Patient Selection; Peripheral Nerves; Peroneal Nerve; Placebos; Pyrazines; Spiro Compounds; Sural Nerve	2006
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clinical therapeutics, 2006, Volume: 28, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Glucagon-Like Peptide 1; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Middle Aged; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles	2006
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:11 Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles	2006
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia, 2006, Volume: 49, Issue:11 Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles	2006
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Current medical research and opinion, 2006, Volume: 22, Issue:10 Topics: Adenosine Deaminase Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2006
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes care, 2006, Volume: 29, Issue:12 Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2006
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes care, 2006, Volume: 29, Issue:12 Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Placebos; Proinsulin; Protease Inhibitors; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles	2006
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International journal of clinical practice, 2007, Volume: 61, Issue:1 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical therapeutics, 2006, Volume: 28, Issue:10 Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2006
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. American journal of physiology. Endocrinology and metabolism, 2007, Volume: 292, Issue:6 Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Genetic Predisposition to Disease; Glucose Clamp Technique; Hormones; Humans; Hyperglycemia; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Osmolar Concentration; Pyrazines; Time Factors	2007
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:2 Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:2 Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes care, 2007, Volume: 30, Issue:8 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Patient Selection; Placebos; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles	2007
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Current medical research and opinion, 2007, Volume: 23, Issue:6 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2007
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes research and clinical practice, 2008, Volume: 79, Issue:2 Topics: Adult; Age of Onset; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Placebos; Pyrazines; Safety; Sitagliptin Phosphate; Triazoles	2008
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Current medical research and opinion, 2008, Volume: 24, Issue:2 Topics: Adult; Aged; Area Under Curve; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2008
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:10 Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides	2008
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia. Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:3 Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides	1995
Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. The Journal of clinical endocrinology and metabolism, 1994, Volume: 78, Issue:3 Topics: Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypolipidemic Agents; Insulin; Lactates; Lactic Acid; Male; Middle Aged; Osmolar Concentration; Placebos; Pyrazines; Time Factors	1994
Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus. Journal of clinical pharmacology, 1993, Volume: 33, Issue:9 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Down-Regulation; Fatty Acids; Female; Glucose Tolerance Test; Guanidines; Humans; Hydrochlorothiazide; Insulin; Male; Middle Aged; Pyrazines; Uremia	1993
Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM. Diabetes, 1993, Volume: 42, Issue:12 Topics: Analysis of Variance; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Gluconeogenesis; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Lactates; Lipolysis; Liver; Male; Middle Aged; Oxygen Consumption; Pyrazines; Tritium	1993
Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial. Diabetes care, 1993, Volume: 16, Issue:9 Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipids; Lipoproteins; Male; Middle Aged; Pyrazines; Triglycerides	1993
Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes, 1993, Volume: 42, Issue:11 Topics: Blood Glucose; Calorimetry; Chromatography, High Pressure Liquid; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Pyrazines; Time Factors	1993
The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 1993, Volume: 10, Issue:2 Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Calorimetry; Carbon Dioxide; Diabetes Mellitus, Type 2; Energy Metabolism; Exercise; Fatty Acids, Nonesterified; Female; Glucagon; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Nitrogen; Oxygen Consumption; Pyrazines; Reference Values	1993
Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate. Metabolism: clinical and experimental, 1993, Volume: 42, Issue:3 Topics: Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucagon; Glucose; Glycerol; Growth Hormone; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Lipid Metabolism; Male; Oxidation-Reduction; Pyrazines; Pyruvates; Radioimmunoassay; Time Factors	1993
The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus. Metabolism: clinical and experimental, 1993, Volume: 42, Issue:4 Topics: 3-Hydroxybutyric Acid; Acetoacetates; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Glycerol; Growth Hormone; Heparin; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Ketone Bodies; Male; Middle Aged; Norepinephrine; Pyrazines; Triglycerides	1993
Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids. Metabolism: clinical and experimental, 1993, Volume: 42, Issue:5 Topics: Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Forearm; Glucose; Hormones; Humans; Hypolipidemic Agents; Insulin; Liver; Male; Middle Aged; Osmolar Concentration; Pyrazines	1993
Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients. Diabetologia, 1996, Volume: 39, Issue:1 Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Forearm; Glucose; Glucose Tolerance Test; Glycerol; Glycogen; Humans; Hydroxybutyrates; Hypolipidemic Agents; Kinetics; Middle Aged; Muscle, Skeletal; Pyrazines; Regional Blood Flow; Thinness; Time Factors	1996
Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control. Diabetes research and clinical practice, 1997, Volume: 36, Issue:2 Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Triglycerides	1997
Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus. Metabolism: clinical and experimental, 1998, Volume: 47, Issue:3 Topics: Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Male; Placebos; Pyrazines; Triglycerides	1998
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia, 1998, Volume: 41, Issue:10 Topics: Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Oxygen Consumption; Placebos; Pyrazines	1998
Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia. Journal of clinical pharmacology, 1998, Volume: 38, Issue:10 Topics: Adult; Aged; Anticholesteremic Agents; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines	1998
Intensive lipid-lowering strategy in patients with diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 1999, Volume: 16, Issue:6 Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides	1999
Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes, 1999, Volume: 48, Issue:8 Topics: Adult; Carrier Proteins; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Glycoproteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Pyrazines; Reference Values; Time Factors	1999
Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results. Nuclear medicine communications, 1998, Volume: 19, Issue:9 Topics: Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Clamp Technique; Heart; Humans; Hyperinsulinism; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pyrazines; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed	1998
The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients. European journal of endocrinology, 2000, Volume: 143, Issue:3 Topics: Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Insulin; Leptin; Male; Middle Aged; Niacin; Pyrazines; Triglycerides	2000
The role of free fatty acids (FFA) in the regulation of intrahepatic fluxes of glucose and glycogen metabolism during short-term starvation in healthy volunteers. Clinical nutrition (Edinburgh, Scotland), 2001, Volume: 20, Issue:2 Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acids, Nonesterified; Food Deprivation; Gluconeogenesis; Glucose; Glycogen; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Pyrazines	2001
Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox. Clinical science (London, England : 1979), 1992, Volume: 82, Issue:5 Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesterified; Glucagon; Glycerol; Humans; Hydrocortisone; Hydroxybutyrates; Hypolipidemic Agents; Lipolysis; Male; Middle Aged; Norepinephrine; Pyrazines	1992
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes, 1992, Volume: 41, Issue:11 Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glycerol; Humans; Hydroxybutyrates; Hypolipidemic Agents; Insulin; Lactates; Male; Middle Aged; Obesity; Pyrazines; Pyruvates; Triglycerides	1992
Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta endocrinologica, 1992, Volume: 127, Issue:4 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metabolism; Female; Glucose; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pyrazines; Time Factors	1992
A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 1992, Volume: 9, Issue:10 Topics: Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Male; Middle Aged; Pyrazines; Triglycerides	1992
[Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes]. Casopis lekaru ceskych, 1991, Nov-29, Volume: 130, Issue:22-23 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrazines	1991

Other Studies

238 other study(ies) available for pyrazines and Diabetes Mellitus, Type 2

Article	Year
Tetramethylpyrazine alleviates diabetes-induced high platelet response and endothelial adhesion via inhibiting NLRP3 inflammasome activation. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 96 Topics: Animals; Blood Platelets; Diabetes Mellitus, Type 2; Human Umbilical Vein Endothelial Cells; Humans; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; NLR Proteins; Pyrazines; Rats	2022
Tetramethylpyrazine Attenuates Cognitive Impairment Via Suppressing Oxidative Stress, Neuroinflammation, and Apoptosis in Type 2 Diabetic Rats. Neurochemical research, 2022, Volume: 47, Issue:8 Topics: Acetylcholinesterase; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Maze Learning; Neuroinflammatory Diseases; Oxidative Stress; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Rats, Sprague-Dawley	2022
Tetramethylpyrazine prevents diabetes by activating PI3K/Akt/GLUT-4 signalling in animal model of type-2 diabetes. Life sciences, 2019, Nov-01, Volume: 236 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Glucose Transporter Type 4; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Vasodilator Agents	2019
Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats. European journal of pharmacology, 2019, Dec-15, Volume: 865 Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Kidney; Kidney Failure, Chronic; Male; Oxidative Stress; Protective Agents; Proto-Oncogene Proteins c-akt; Pyrazines; Rats, Wistar; Signal Transduction	2019
[Ligustrazine alleviates the tissue injury of the submandibular glands by enhanceing the antioxidant and anti-inflammatory effects in diabetic rats]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2021, Volume: 37, Issue:3 Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Pyrazines; Rats; Rats, Sprague-Dawley; Submandibular Gland	2021
Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:3 Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Pilot Projects; Postprandial Period; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovascular diabetology, 2013, Feb-21, Volume: 12 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycemic Index; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2013
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA internal medicine, 2013, Apr-08, Volume: 173, Issue:7 Topics: Acute Disease; Adolescent; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Hospitalization; Humans; Logistic Models; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms	2013
Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows. BMJ (Clinical research ed.), 2013, Feb-27, Volume: 346 Topics: Acute Disease; Animals; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Exenatide; Humans; Hypoglycemic Agents; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms	2013
DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatology international, 2014, Volume: 34, Issue:2 Topics: Adamantane; Arthritis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Sitagliptin--another option for managing type 2 diabetes in dialysis patients? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013, Volume: 61, Issue:4 Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Pancreatitis associated with incretin-based therapies. Diabetes care, 2013, Volume: 36, Issue:4 Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2013
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes, 2013, Volume: 62, Issue:7 Topics: Adenoma; Adolescent; Adult; Aged; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hyperplasia; Incretins; Insulin-Secreting Cells; Male; Middle Aged; Neuroendocrine Tumors; Organ Size; Pancreas; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects. The Journal of physiology, 2013, Jun-01, Volume: 591, Issue:11 Topics: Administration, Oral; Adult; Case-Control Studies; Ceramides; Chemokine CCL2; Diabetes Mellitus, Type 2; Diglycerides; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypolipidemic Agents; I-kappa B Kinase; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Middle Aged; Muscle, Skeletal; Obesity; Pyrazines; Signal Transduction; Toll-Like Receptor 4	2013
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovascular diabetology, 2013, Mar-28, Volume: 12 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Length of Stay; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Pyrazines; Retrospective Studies; Secondary Prevention; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2013
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. Journal of managed care pharmacy : JMCP, 2013, Volume: 19, Issue:3 Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Substitution; Glucagon-Like Peptide 1; Glycemic Index; Health Care Costs; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Failure; Triazoles; United States	2013
Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database. International journal of clinical practice, 2013, Volume: 67, Issue:5 Topics: Administration, Oral; Adult; Age Distribution; Diabetes Mellitus, Type 2; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; United States	2013
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. The Journal of endocrinology, 2013, Volume: 218, Issue:1 Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ (Clinical research ed.), 2013, Apr-25, Volume: 346 Topics: Comparative Effectiveness Research; Confounding Factors, Epidemiologic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Insurance, Health; Male; Middle Aged; Myocardial Ischemia; Practice Guidelines as Topic; Propensity Score; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; United States	2013
Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:5 Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Should we be reassured about sitagliptin? BMJ (Clinical research ed.), 2013, May-14, Volume: 346 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles	2013
[Diabetes treatment in patients with chronic kidney disease]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:21 Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Kidney Function Tests; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats. Endocrine, 2014, Volume: 45, Issue:2 Topics: Animals; C-Peptide; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Treatment Outcome; Triazoles; Umbilical Cord	2014
Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. Journal of managed care pharmacy : JMCP, 2013, Volume: 19, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Exenatide; Female; Health Care Costs; Humans; Hypoglycemic Agents; Linear Models; Male; Medicare Part D; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult	2013
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients. Diabetes care, 2013, Volume: 36, Issue:10 Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hypoglycemic Agents; Inflammation; Logistic Models; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2013
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. American journal of physiology. Endocrinology and metabolism, 2013, Aug-15, Volume: 305, Issue:4 Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hemizygote; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Metformin; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Pancreatitis; Plaque, Amyloid; Pyrazines; Random Allocation; Recombinant Proteins; Sitagliptin Phosphate; Time Factors; Triazoles	2013
Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes? BMJ (Clinical research ed.), 2013, Jun-04, Volume: 346 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles	2013
Authors' reply to de Oliveira. BMJ (Clinical research ed.), 2013, Jun-04, Volume: 346 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles	2013
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. Journal of Korean medical science, 2013, Volume: 28, Issue:6 Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study. Mutation research, 2013, Sep-18, Volume: 757, Issue:1 Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Micronuclei, Chromosome-Defective; Middle Aged; Pilot Projects; Pioglitazone; Pyrazines; Rosiglitazone; Sister Chromatid Exchange; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2013
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists. Journal of diabetes, 2014, Volume: 6, Issue:2 Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms	2014
An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:8 Topics: Adolescent; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hyperplasia; Hypoglycemic Agents; Incretins; Male; Middle Aged; Models, Statistical; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Tissue Banks; Triazoles; Venoms; Young Adult	2013
Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Diabetes research and clinical practice, 2013, Volume: 102, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Arthritis; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Sitagliptin: results from clinical practice. Current medical research and opinion, 2013, Volume: 29, Issue:11 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
In reply to 'Primary objective of study of sitagliptin in patients with ESRD on dialysis'. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013, Volume: 62, Issue:3 Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Triazoles	2013
Primary objective of study of sitagliptin in patients with ESRD on dialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013, Volume: 62, Issue:3 Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Triazoles	2013
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles	2014
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]. Revue medicale de Liege, 2013, Volume: 68, Issue:10 Topics: Belgium; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles	2013
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PloS one, 2013, Volume: 8, Issue:10 Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles	2013
Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2013, Volume: 64, Issue:5 Topics: Acetylcholine; Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Hypothalamus; Insulin; Lipids; Male; Memory; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; Sitagliptin Phosphate; Triazoles	2013
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6 Topics: Adamantane; Adaptive Immunity; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Immunity, Innate; Mice; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; T-Lymphocytes; Triazoles; Vildagliptin	2014
Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals. Diabetes, 2014, Volume: 63, Issue:8 Topics: Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Mitochondria; Obesity; Pyrazines; Reactive Oxygen Species	2014
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats. The Journal of endocrinology, 2014, Volume: 220, Issue:3 Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles	2014
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin. Endocrinology, 2014, Volume: 155, Issue:3 Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Keratins; Ki-67 Antigen; Male; Metformin; Pancreas, Exocrine; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles	2014
Comment on Du Q, Wu B, Wang YJ, et al. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin 2013;29:1487-94. Current medical research and opinion, 2014, Volume: 30, Issue:6 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Triazoles	2014
[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2014, Volume: 134, Issue:2 Topics: Acarbose; Administration, Oral; Adverse Drug Reaction Reporting Systems; Benzamides; Biguanides; Data Mining; Databases, Pharmaceutical; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Pyrazines; Risk; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles	2014
Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study. Diabetes research and clinical practice, 2014, Volume: 103, Issue:3 Topics: Adult; Asian People; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles	2014
Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes. Primary care diabetes, 2014, Volume: 8, Issue:3 Topics: Aged; Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Japan; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2014
SGLT2 versus DPP4 inhibitors for type 2 diabetes. The lancet. Diabetes & endocrinology, 2013, Volume: 1, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Triazoles	2013
Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes care, 2014, Volume: 37, Issue:5 Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States	2014
Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. Journal of diabetes, 2015, Volume: 7, Issue:1 Topics: Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2015
Management of a prediabetes case with the DPP-4 inhibitor sitagliptin. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:6 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Middle Aged; Prediabetic State; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes. British journal of pharmacology, 2014, Volume: 171, Issue:7 Topics: Animals; Azetidines; Biomarkers; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Administration Schedule; Enzyme Activation; Enzyme Activators; Glucokinase; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Knockout; Pyrazines; Rats; Rats, Zucker; Sulfones; Thiadiazoles; Translational Research, Biomedical; Triglycerides	2014
Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A. Cell biochemistry and biophysics, 2014, Volume: 70, Issue:2 Topics: Amino Acid Sequence; Conserved Sequence; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hydrogen Bonding; Hypoglycemic Agents; Ligands; Molecular Dynamics Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Protein Processing, Post-Translational; Protein Structure, Secondary; Protein Subunits; Pyrazines; Sitagliptin Phosphate; Surface Properties; Triazoles	2014
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators of inflammation, 2014, Volume: 2014 Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Inflammation; Kidney; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Tumor Necrosis Factor-alpha	2014
Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes. The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:8 Topics: Adult; Aged; Amylases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipase; Male; Middle Aged; Pancreatitis; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles	2013
Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus. Postgraduate medicine, 2014, Volume: 126, Issue:3 Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles	2014
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. Journal of medical economics, 2014, Volume: 17, Issue:9 Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles	2014
Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC. Heart failure, 2014, Volume: 2, Issue:6 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014
Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? JACC. Heart failure, 2014, Volume: 2, Issue:6 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Male; Pyrazines; Triazoles	2014
Dapagliflozin--do we need it registered for type 2 diabetes? Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:11 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles	2014
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. Journal of pharmacological sciences, 2014, Volume: 125, Issue:4 Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation	2014
Improved mitochondrial function is linked with improved insulin sensitivity through reductions in FFA. Diabetes, 2014, Volume: 63, Issue:8 Topics: Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin Resistance; Male; Mitochondria; Obesity; Pyrazines	2014
Diabetes: safety and efficacy of albiglutide-results from two trials. Nature reviews. Endocrinology, 2014, Volume: 10, Issue:9 Topics: Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Pyrazines; Sulfonylurea Compounds; Triazoles	2014
Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. American journal of physiology. Cell physiology, 2014, Nov-01, Volume: 307, Issue:9 Topics: Boronic Acids; Bortezomib; Cells, Cultured; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose; Glycogen; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Male; Muscle, Skeletal; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Carbonylation; Proteome; Pyrazines; RNA Interference; Signal Transduction	2014
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes. Endocrine journal, 2014, Volume: 61, Issue:12 Topics: Administration, Oral; Aged; Algorithms; Biomarkers; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Japan; Male; Proinsulin; Pyrazines; Sitagliptin Phosphate; Triazoles	2014
Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC health services research, 2014, Sep-22, Volume: 14 Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Greece; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2014
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:12 Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2014
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics]. MMW Fortschritte der Medizin, 2014, Jul-24, Volume: 156, Issue:13 Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes? Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:18 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles	2014
Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of gelsolin. Journal of diabetes research, 2014, Volume: 2014 Topics: Actins; Adult; Animals; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Down-Regulation; Female; Gelsolin; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Peptide Fragments; Polymerization; Pyrazines; Recombinant Proteins; Sitagliptin Phosphate; Streptozocin; Time Factors; Triazoles	2014
A novel data-mining approach leveraging social media to monitor consumer opinion of sitagliptin. IEEE journal of biomedical and health informatics, 2015, Volume: 19, Issue:1 Topics: Attitude to Health; Consumer Behavior; Data Mining; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Information Dissemination; Natural Language Processing; Patient Satisfaction; Public Opinion; Pyrazines; Sitagliptin Phosphate; Social Media; Triazoles; Vocabulary, Controlled	2015
Author’s response. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:18 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles	2014
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study. Medicine, 2015, Volume: 94, Issue:28 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles	2015
[Sitagliptin in diabetes: Severe side effects are rare]. Praxis, 2015, Sep-02, Volume: 104, Issue:18 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles	2015
[Type 2 diabetes: Cardiovascular long-term safety of sitagliptin demonstrated]. Praxis, 2015, Nov-11, Volume: 104, Issue:23 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles	2015
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2015, 12-17, Volume: 373, Issue:25 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles	2015
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2015, 12-17, Volume: 373, Issue:25 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles	2015
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2015, 12-17, Volume: 373, Issue:25 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles	2015
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2015, 12-17, Volume: 373, Issue:25 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles	2015
Sitagliptin and other 'gliptins'--why prescribe them? Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:6 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles	2016
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose. Pathobiology : journal of immunopathology, molecular and cellular biology, 2016, Volume: 83, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors	2016
Sitagliptin and Risk of Heart Failure in Patients With Type 2 Diabetes: A Meta-Analysis. JACC. Heart failure, 2016, Volume: 4, Issue:11 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Pyrazines; Risk; Sitagliptin Phosphate	2016
Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. The EMBO journal, 2008, Jul-23, Volume: 27, Issue:14 Topics: Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Humans; Imidazoles; Mutation; Phosphorylation; Pyrazines; Receptor, IGF Type 1	2008
Three new drugs for type 2 diabetes. Drug and therapeutics bulletin, 2008, Volume: 46, Issue:7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2008
Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus. American journal of physiology. Endocrinology and metabolism, 2008, Volume: 295, Issue:3 Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Caloric Restriction; Cholesterol; Diabetes Mellitus, Type 2; Diastole; Fatty Acids, Nonesterified; Glycated Hemoglobin; Heart Rate; Humans; Hypolipidemic Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyrazines; Triglycerides	2008
[Sitagliptin]. Revue de l'infirmiere, 2008, Issue:144 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Patient Selection; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles	2008
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Current drug targets, 2009, Volume: 10, Issue:1 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Treatment Outcome; Triazoles; Vildagliptin	2009
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Advances in therapy, 2009, Volume: 26, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cost Savings; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Emergency Service, Hospital; Exenatide; Female; Glycated Hemoglobin; Health Care Costs; Health Services Research; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms	2009
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1). Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:2 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles	2009
Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes. American family physician, 2009, Mar-01, Volume: 79, Issue:5 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2009
Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable. Prescrire international, 2009, Volume: 18, Issue:99 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Europe; Humans; Pyrazines; Sulfonylurea Compounds; Triazoles	2009
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes, 2009, Volume: 58, Issue:7 Topics: Amyloid; Animals; Animals, Genetically Modified; Arginine; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Metformin; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles	2009
By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I Harvard health letter, 2009, Volume: 34, Issue:7 Topics: Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. Prescrire international, 2009, Volume: 18, Issue:101 Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Drug Synergism; Europe; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Sulfonylurea Compounds; Triazoles	2009
Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:7 Topics: Ambulatory Care Facilities; Cohort Studies; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Utilization Review; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney Function Tests; Medication Errors; Pharmacists; Private Sector; Professional Role; Pyrazines; Renal Insufficiency; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States	2009
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. European journal of pharmacology, 2009, Nov-25, Volume: 623, Issue:1-3 Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Ki-67 Antigen; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides	2009
Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:8 Topics: Adamantane; Cinnamomum zeylanicum; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2009
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths]. MMW Fortschritte der Medizin, 2009, May-07, Volume: 151, Issue:19 Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss	2009
[Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia]. MMW Fortschritte der Medizin, 2009, Oct-15, Volume: 151, Issue:42 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles	2009
[Combination antidiabetic therapy. Better control of blood glucose values]. MMW Fortschritte der Medizin, 2009, Oct-15, Volume: 151, Issue:42 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2009
Initial therapy for type 2 diabetes. Examination of a combination approach. Advance for nurse practitioners, 2009, Volume: 17, Issue:6 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Practice; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nurse Practitioners; Practice Guidelines as Topic; Primary Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. Journal of diabetes science and technology, 2009, Volume: 3, Issue:1 Topics: Body Weight; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Models, Theoretical; Pyrazines; Sitagliptin Phosphate; Triazoles	2009
Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes care, 2010, Volume: 33, Issue:4 Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Triazoles; Venoms	2010
Elevated hepatic enzymes potentially associated with sitagliptin. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:2 Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Humans; Liver; Liver Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2010, Volume: 118, Issue:8 Topics: Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Lipopolysaccharide Receptors; Male; Membrane Proteins; Middle Aged; Monocytes; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:7 Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents	2010
New therapeutic options: management strategies to optimize glycemic control. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms	2010
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes care, 2010, Volume: 33, Issue:8 Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database. Advances in therapy, 2010, Volume: 27, Issue:4 Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms	2010
[New hypoglycemic agents in type 2 diabetes]. La Revue du praticien, 2010, Apr-20, Volume: 60, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2010
Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. Current medical research and opinion, 2010, Volume: 26, Issue:7 Topics: Administration, Oral; Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Electronic Health Records; Humans; Hyperglycemia; Hypoglycemic Agents; Individuality; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States	2010
Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:4 Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Lactones; Middle Aged; Orlistat; Pancreatitis; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:4 Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Irbesartan; Pyrazines; Sitagliptin Phosphate; Tetrazoles; Treatment Outcome; Triazoles	2010
Choosing among the incretin agents and why it matters. The Journal of family practice, 2010, Volume: 59, Issue:5 Suppl Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Individualised incretin-based treatment for type 2 diabetes. Lancet (London, England), 2010, Aug-07, Volume: 376, Issue:9739 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2010
Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Archives of internal medicine, 2010, Jul-12, Volume: 170, Issue:13 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Hypersensitivity; Female; Glucagon-Like Peptide 1; Humans; Incidence; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States	2010
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators of inflammation, 2010, Volume: 2010 Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Glycated Hemoglobin; Insulin; Insulin Resistance; Interleukin-1beta; Lipids; Male; Oxidative Stress; Pancreas; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles	2010
Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 56, Issue:4 Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Enalapril; Heart Rate; Hemodynamics; Humans; Metabolic Syndrome; Models, Biological; Peptidyl-Dipeptidase A; Pyrazines; Sitagliptin Phosphate; Triazoles	2010
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes care, 2010, Volume: 33, Issue:11 Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatitis; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Venoms	2010
Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regulatory peptides, 2011, Jan-17, Volume: 166, Issue:1-3 Topics: Animals; Apoptosis; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA Fragmentation; Female; Glutathione; Glutathione Peroxidase; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Oxidative Stress; Peroxidase; Pyrazines; Rats; Rats, Wistar; Reperfusion Injury; Sitagliptin Phosphate; Superoxide Dismutase; Triazoles; Xanthine Oxidase	2011
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Patient education and self-management. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Introduction. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. International journal of clinical practice, 2010, Volume: 64, Issue:12 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Health Status; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Acceptance of Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles; United States	2010
Severe leucopenia associated with Sitagliptin use. Diabetes research and clinical practice, 2011, Volume: 91, Issue:2 Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Leukopenia; Male; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose]. MMW Fortschritte der Medizin, 2010, Oct-07, Volume: 152, Issue:40 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2010
Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience. Diabetes technology & therapeutics, 2011, Volume: 13, Issue:1 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; India; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles; Triglycerides	2011
[Medication of the month. Sitagliptin-metformin fixed combination (Janumet)]. Revue medicale de Liege, 2010, Volume: 65, Issue:11 Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination	2010
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:4 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2011
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemporary clinical trials, 2011, Volume: 32, Issue:3 Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin	2011
Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis. Angewandte Chemie (International ed. in English), 2011, Feb-25, Volume: 50, Issue:9 Topics: Biocatalysis; Diabetes Mellitus, Type 2; Green Chemistry Technology; Humans; Pyrazines; Ruthenium; Sitagliptin Phosphate; Transaminases; Triazoles	2011
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011, Volume: 141, Issue:1 Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms	2011
Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats. Experimental biology and medicine (Maywood, N.J.), 2011, Volume: 236, Issue:3 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Feeding Behavior; Glucagon; Glucagon-Like Peptide 1; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles	2011
Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates. Clinical science (London, England : 1979), 2011, Volume: 121, Issue:4 Topics: Adenosine Triphosphate; Blood Glucose; Breath Tests; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glycogen; Humans; Hypolipidemic Agents; Insulin; Lipolysis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Muscles; Pyrazines	2011
Journal withdraws article after complaints from drug manufacturers. BMJ (Clinical research ed.), 2011, Apr-11, Volume: 342 Topics: Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Periodicals as Topic; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2011
A case of drug-induced hepatic injury associated with sitagliptin. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:9 Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Jaundice; Liver; Male; Microscopy, Electron, Transmission; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
A diabetes drug, sitagliptin, also has a potential to prevent diabetes. Experimental biology and medicine (Maywood, N.J.), 2011, Volume: 236, Issue:3 Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin Secretion; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles	2011
[Incretin enhancer: sitagliptin]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:5 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
DPP-IV inhibitor may affect spermatogenesis. Diabetes research and clinical practice, 2011, Volume: 93, Issue:2 Topics: Adult; Amoxapine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ejaculation; Humans; Male; Neurotransmitter Uptake Inhibitors; Pyrazines; Semen Analysis; Sitagliptin Phosphate; Spermatogenesis; Triazoles	2011
GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology, 2011, Volume: 141, Issue:1 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms	2011
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clinical drug investigation, 2011, Volume: 31, Issue:9 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2011
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; United Kingdom; Young Adult	2012
Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. The Journal of dermatology, 2012, Volume: 39, Issue:8 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Middle Aged; Pruritus; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles	2012
Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4? Gastroenterology, 2011, Volume: 141, Issue:6 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Thyroid Neoplasms; Triazoles; Venoms	2011
The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes research and clinical practice, 2012, Volume: 95, Issue:1 Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology (Basel, Switzerland), 2012, Volume: 224, Issue:1 Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Psoriasis; Pyrazines; Sitagliptin Phosphate; T-Lymphocytes; Treatment Outcome; Triazoles	2012
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Translational research : the journal of laboratory and clinical medicine, 2012, Volume: 159, Issue:1 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Triazoles	2012
Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. Endocrine journal, 2012, Volume: 59, Issue:3 Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Japan; Life Style; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:1 Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms	2012
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovascular diabetology, 2011, Dec-22, Volume: 10 Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental diabetes research, 2011, Volume: 2011 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Insulin; Kidney Glomerulus; Lipid Peroxidation; Lipids; Male; Obesity; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2011
Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. Neurobiology of disease, 2012, Volume: 46, Issue:1 Topics: Alzheimer Disease; Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Male; Neurons; Phosphorylation; Primary Cell Culture; Pyrazines; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Sitagliptin Phosphate; tau Proteins; Triazoles	2012
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:7 Topics: Acute Kidney Injury; Adolescent; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Exenatide; Female; Humans; Incidence; Male; Middle Aged; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult	2012
Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:7 Topics: Animals; Apolipoprotein B-100; Biological Transport; Biomarkers; Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Intestinal Absorption; Lipoproteins, HDL; Macrophages; Male; Metformin; Mice; Mice, Obese; Mice, Transgenic; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. American journal of physiology. Gastrointestinal and liver physiology, 2012, Apr-15, Volume: 302, Issue:8 Topics: Allylamine; Animals; Anticholesteremic Agents; Apoptosis; Bile Acids and Salts; Blood Glucose; Body Weight; Cell Proliferation; Cell Size; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Diet; Drug Synergism; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin; Insulin-Secreting Cells; Ki-67 Antigen; Male; Postprandial Period; Pyrazines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; RNA, Messenger; Sitagliptin Phosphate; Triazoles	2012
Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor. The Australasian journal of dermatology, 2012, Volume: 53, Issue:1 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Extremities; Female; Humans; Middle Aged; Psoriasis; Pyrazines; Sitagliptin Phosphate; Torso; Triazoles	2012
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. Journal of medical economics, 2012, Volume: 15, Issue:4 Topics: Adult; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Humans; Hypoglycemic Agents; Long-Term Care; Male; Markov Chains; Middle Aged; Models, Theoretical; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; United States; Venoms	2012
Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study. PloS one, 2012, Volume: 7, Issue:2 Topics: Adult; Aged; Body Mass Index; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Overweight; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Weight Loss	2012
Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®). Dermatology online journal, 2012, Feb-15, Volume: 18, Issue:2 Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Photosensitivity Disorders; Protective Clothing; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
[Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)]. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47 Suppl D Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2011
Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Humans; Islets of Langerhans; Losartan; Male; Mice; Pyrazines; Regeneration; Sitagliptin Phosphate; Stem Cells; Triazoles	2012
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10 Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy. Endocrine research, 2012, Volume: 37, Issue:4 Topics: Aged; Blood Glucose; Blood Pressure; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Weight Gain	2012
Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Jun-15, Volume: 69, Issue:12 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2012
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia, 2012, Volume: 55, Issue:8 Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Immunohistochemistry; Lipid Metabolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Choosing a blood-glucose-lowering agent after metformin. Lancet (London, England), 2012, Jun-16, Volume: 379, Issue:9833 Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Serum level of soluble CD26/dieptidyl peptidase-4 (DPP-4) activity correlates with other liver disease biomarkers both in Asian and European patients. Translational research : the journal of laboratory and clinical medicine, 2012, Volume: 160, Issue:1 Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles	2012
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value. Current medical research and opinion, 2012, Volume: 28, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles	2012
Re: Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4). Translational research : the journal of laboratory and clinical medicine, 2012, Volume: 160, Issue:2 Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Pyrazines; Triazoles	2012
[Therapeutic use and adverse events of incretin-related drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2012
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. Journal of medical economics, 2012, Volume: 15 Suppl 2 Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Markov Chains; Metformin; Outcome Assessment, Health Care; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocrine journal, 2012, Volume: 59, Issue:12 Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2012
Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:15 Topics: Alleles; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Genetic Predisposition to Disease; HLA-DRB1 Chains; Humans; Middle Aged; Pyrazines; Rheumatoid Factor; Sitagliptin Phosphate; Triazoles	2012
Mechanism of action of DPP-4 inhibitors--new insights. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:8 Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta gastro-enterologica Belgica, 2012, Volume: 75, Issue:2 Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Hepatocytes; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats. The Journal of nutrition, 2012, Volume: 142, Issue:10 Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Obesity; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Satiation; Sitagliptin Phosphate; Triazoles	2012
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. TheScientificWorldJournal, 2012, Volume: 2012 Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Inflammation; Liraglutide; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pioglitazone; Platelet Count; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles	2012
Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets, 2012, Volume: 23, Issue:8 Topics: Adult; Aged; Blood Platelets; Blood Proteins; Calcium; Case-Control Studies; Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Sitagliptin Phosphate; Thrombin; Triazoles; Tyrosine	2012
[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction]. MMW Fortschritte der Medizin, 2012, Aug-23, Volume: 154, Issue:14 Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sitagliptin Phosphate; Survival Rate; Triazoles	2012
Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism: clinical and experimental, 2013, Volume: 62, Issue:1 Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Nude; Nateglinide; Peptides; Phenylalanine; Pyrazines; Sitagliptin Phosphate; Specific Pathogen-Free Organisms; Triazoles; Venoms	2013
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory peptides, 2012, Nov-10, Volume: 179, Issue:1-3 Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Adenoma; Anatomy, Cross-Sectional; Animals; Chlorocebus aethiops; Colon; Colonic Neoplasms; COS Cells; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide-2 Receptor; Hypoglycemic Agents; Intestinal Mucosa; Intestine, Small; Liraglutide; Mice; Mice, Inbred C57BL; Organ Size; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Transfection; Triazoles; Venoms	2012
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. European journal of pharmacology, 2012, Dec-05, Volume: 696, Issue:1-3 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin	2012
Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates. British journal of anaesthesia, 2012, Volume: 109, Issue:5 Topics: Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation Factors; Bradykinin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypertension; Laryngeal Diseases; Male; Perindopril; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23 Topics: Administration, Oral; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Drug Design; Glucokinase; Glucose Tolerance Test; Half-Life; Humans; Hypoglycemic Agents; Indazoles; Insulin; Kinetics; Protein Binding; Pyrazines; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2012
Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin. Diabetes & metabolism, 2012, Volume: 38, Issue:6 Topics: Acute Kidney Injury; Aged; Back; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ear; Edema; Eosinophilia; Exanthema; Female; Glucocorticoids; Humans; Prednisone; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Bortezomib induced a phrenic palsy in a multiple myeloma patient. Annals of hematology, 2013, Volume: 92, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid	2013
Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%. Journal of endocrinological investigation, 2013, Volume: 36, Issue:8 Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:5 Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Inflammation Mediators; Linear Models; Logistic Models; Male; Manometry; Middle Aged; Multivariate Analysis; Odds Ratio; Peripheral Arterial Disease; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2013
Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:5 Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Male; Peripheral Arterial Disease; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocrine journal, 2013, Volume: 60, Issue:6 Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles	2013
Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. American journal of physiology. Endocrinology and metabolism, 2003, Volume: 284, Issue:1 Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dietary Proteins; Energy Intake; Exercise; Fasting; Fatty Acids; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Proinsulin; Pyrazines	2003
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:9 Topics: Adiponectin; Adult; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Interleukin-6; Male; Proteins; Pyrazines; Tumor Necrosis Factor-alpha	2004
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of medicinal chemistry, 2005, Jan-13, Volume: 48, Issue:1 Topics: Administration, Oral; Animals; Binding Sites; Biochemistry; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Models, Molecular; Peptide Fragments; Protein Conformation; Protein Precursors; Pyrazines; Rats; Sitagliptin Phosphate; Structure-Activity Relationship; Triazoles	2005
Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox. Scandinavian journal of clinical and laboratory investigation, 2005, Volume: 65, Issue:6 Topics: Adiponectin; Adult; Aged; Depression, Chemical; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose Clamp Technique; Half-Life; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Lipolysis; Male; Middle Aged; Pyrazines; Time Factors	2005
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes, 2006, Volume: 55, Issue:6 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Disease Models, Animal; Dyslipidemias; Glipizide; Hypoglycemic Agents; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred ICR; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2006
[DPP-4 inhibition raises incretin levels]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:8 Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Humans; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles	2006
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. Geriatrics, 2006, Volume: 61, Issue:9 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic & medicinal chemistry letters, 2007, Jan-01, Volume: 17, Issue:1 Topics: Animals; Azepines; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Protease Inhibitors; Protein Conformation; Pyrazines; Rats; Rats, Inbred Strains; Sitagliptin Phosphate; Triazoles	2007
First-in-class diabetes drug approved. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Dec-01, Volume: 63, Issue:23 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2006
Sitagliptin (Januvia) for type 2 diabetes. The Medical letter on drugs and therapeutics, 2007, Jan-01, Volume: 49, Issue:1251 Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
Finding new treatments for diabetes--how many, how fast... how good? The New England journal of medicine, 2007, Feb-01, Volume: 356, Issue:5 Topics: Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Glucagon-Like Peptide 1; Glycoproteins; History, 20th Century; History, 21st Century; Humans; Hypoglycemic Agents; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration	2007
Sitagliptin. Nature reviews. Drug discovery, 2007, Volume: 6, Issue:2 Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2007
Sitagliptin: a viewpoint by Mark S. Kipnes. Drugs, 2007, Volume: 67, Issue:4 Topics: Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
Sitagliptin: a viewpoint by Itamar Raz. Drugs, 2007, Volume: 67, Issue:4 Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes care, 2007, Volume: 30, Issue:7 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Triazoles	2007
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adenosine Deaminase Inhibitors; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2007
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration	2007
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration	2007
Sitagliptin/metformin (Janumet) for type 2 diabetes. The Medical letter on drugs and therapeutics, 2007, Jun-04, Volume: 49, Issue:1262 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2007
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:4 Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Janumet. JAAPA : official journal of the American Academy of Physician Assistants, 2007, Volume: 20, Issue:6 Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
[New class of oral antidiabetic drugs. Effective in combination with metformin]. MMW Fortschritte der Medizin, 2007, Volume: 149, Issue:1-2 Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2007
Treatment of type 2 diabetes mellitus and the incretin system. South Dakota medicine : the journal of the South Dakota State Medical Association, 2007, Volume: 60, Issue:5 Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms	2007
Type 2 diabetes: the end of clinical inertia. Southern medical journal, 2007, Volume: 100, Issue:8 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2007
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:10 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles	2007
Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks. Prescrire international, 2008, Volume: 17, Issue:93 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Triazoles	2008
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]. Revue medicale de Liege, 2008, Volume: 63, Issue:2 Topics: Belgium; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Pyrazines; Sitagliptin Phosphate; Triazoles	2008
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes, obesity & metabolism, 2008, Volume: 10 Suppl 1 Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles	2008
[Sitagliptine (Januvia)]. Journal de pharmacie de Belgique, 2008, Volume: 63, Issue:1 Topics: Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Incretins; Pyrazines; Sitagliptin Phosphate; Triazoles	2008
Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clinical therapeutics, 2008, Volume: 30, Issue:4 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Pyrazines; Sitagliptin Phosphate; Sympathetic Nervous System; Treatment Outcome; Triazoles	2008
Pyrazinoylguanidine downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients. Journal of clinical pharmacology, 1994, Volume: 34, Issue:12 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Fatty Acids; Female; Glucose Tolerance Test; Guanidines; Humans; Hypertension; Male; Middle Aged; Pyrazines	1994
Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1994, Volume: 35, Issue:6 Topics: Adult; Aged; Coronary Angiography; Deoxyglucose; Diabetes Mellitus, Type 2; Echocardiography; Female; Fluorodeoxyglucose F18; Glucose; Glucose Clamp Technique; Heart; Humans; Male; Middle Aged; Myocardial Infarction; Myocardium; Nicotinic Acids; Pyrazines; Radionuclide Ventriculography; Tomography, Emission-Computed	1994
Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 1993, Volume: 10, Issue:10 Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Circadian Rhythm; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucose; Glucose Clamp Technique; Glycerol; Humans; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Lipids; Liver; Male; Middle Aged; Pyrazines; Time Factors; Triglycerides	1993
[Effect of olbetam on hyperlipidemia in NIDDM]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1995, Volume: 26, Issue:4 Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides	1995
Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. The American journal of cardiology, 1997, Oct-01, Volume: 80, Issue:7 Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Logistic Models; Longitudinal Studies; Male; Middle Aged; Pyrazines; Ventricular Premature Complexes	1997
Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia. Acta biologica Hungarica, 1997, Volume: 48, Issue:3 Topics: Apolipoprotein A-I; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Time Factors; Triglycerides; Uric Acid	1997
Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport. Diabetic medicine : a journal of the British Diabetic Association, 2001, Volume: 18, Issue:6 Topics: Animals; Apolipoprotein A-I; Body Mass Index; Carrier Proteins; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Liver Neoplasms, Experimental; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Pyrazines; Rats; Reference Values; Tumor Cells, Cultured	2001
Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1991, Volume: 34, Issue:6 Topics: Administration, Oral; Adult; Biological Transport; Calorimetry; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Heparin; Humans; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Lipid Metabolism; Liver; Middle Aged; Oxidation-Reduction; Palmitates; Pyrazines	1991
Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. The Journal of clinical investigation, 1991, Volume: 88, Issue:4 Topics: Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glycogen Synthase; Humans; Hypolipidemic Agents; Lactates; Lactic Acid; Lipid Metabolism; Middle Aged; Muscles; Oxidation-Reduction; Pyrazines; Pyruvate Dehydrogenase Complex	1991
Acipimox and hypertriglyceridaemia. British journal of hospital medicine, 1990, Volume: 43, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Pyrazines	1990